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A B S T R A C T : N ovel 1-(l-benzoylpiperidin-4-yl)m ethanam ine de­
rivatives with high affinity and selectivity for serotonin 5 -H T 1A 
receptors w ere obtained and tested  in four functional assays:
E R K 1 /2  phosphorylation, adenylyl cyclase inhibition, calcium  
mobilization, and ^-arrestin  recruitm ent. C om pounds 4 4  and 5 6  
(2-m ethylam inophenoxyethyl and 2-(lH -in d o l-4 -y lo xy )e th y l de­
rivatives, respectively) were selected as biased agonists with highly 
differential “signaling fingerprints” that translated into distinct in 
vivo profiles. In vitro, 4 4  showed biased agonism  for E R K 1 /2  
p h o sp h o ry latio n  and, in vivo, it p referen tially  exerted  an 
antidepressant-like effect in the Porsolt forced swim ming test in 
rats. In contrast, com pound 5 6  exhibited a first-in-class profile: it 
preferentially and potently activated ^-arrestin  recruitm ent in vitro
and p otently elicited low er lip retraction  in vivo, a com p onen t o f  “serotonergic syndrom e”. B oth  com pounds showed prom ising  
developability properties. T h e presented 5 -H T 1A receptor-biased agonists, preferentially targeting various signaling pathways, have 
the potential to  b ecom e drug candidates for distinct central nervous system  pathologies and possessing accentuated therapeutic 
activity and reduced side effects.
Article
■  IN TR O D U C TIO N
A lthough serotonin 5 -H T 1A receptors exert a m ajor influence 
on central nervous system  (C N S ) functions such as m ood, 
pain, and m ovem ent and w ere identified several decades ago ,1 ,2 
it is notable that there are still no selective 5 -H T 1A receptor  
agonists approved for therapeutic intervention. T h ere are, of  
course, com m ercialized  drugs that exhibit som e agonist 
properties at 5 -H T 1A receptors, including the anxiolytic  
buspirone (B u spar), the antidepressant vortioxetine (Brintel- 
lix ) , th e  a n tip sy ch o tic  arip ip razole (A b ilify ), and the  
antiparkinsonian brom ocriptine (Parlodel) . 3- 6 H ow ever, all 
o f these com pounds also interact with other targets, including 
other m onoam ine receptors or transporters, and they only 
partially activate 5 -H T 1A receptors (i.e., they function as 
“partial agonists”) .  M o reo v er, such com p oun ds do n ot  
discrim inate betw een subpopulations o f  5 -H T 1A receptors  
which are expressed in different brain regions and that m ediate  
various, som etim es opposing, physiological and behavioral 
responses. F o r  example, activation o f  postsynaptic 5 -H T 1A 
h eterorecep tors in the frontal cortex  elicits procognitive and  
antidepressant effects, w hereas activation  o f  presynaptic
5 -H T 1A autoreceptors is associated with prodepressive effects, 
notably by inhibiting the release o f serotonin in term inal 
regions .7' 8 T hese contrasting effects have long been the object 
of discussion in the search for m ore efficacious antidepressants 
and suggest that indiscriminate activation o f  multiple 5 -H T 1A 
receptor subpopulations m ay lim it the therapeutic efficacy of  
5 -H T 1A receptor agonists or elicit unacceptable side effects. In 
contrast, recent advances have shown that it is possible to  
selectively target 5 -H T 1A receptors in desired brain areas, such  
as the cortex or brain stem , leading to  significantly im proved  
and prom ising therapeutic-like outcom es.
T h e basis for such preferential brain region targeting is the 
em erging con cept o f “biased agonism ” at G -protein-coupled  
recep to rs. A ccu m u lated  studies in recen t years provide
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com pelling evidence that different agonists can preferentially  
activate intracellular signaling via specific effectors, such as 
different G -protein subtypes or ^-arrestins. Given that coupling  
to  particular signaling m echanism s can vary from  one brain 
region to  another, this provides a basis for biased agonists to  
differentially activate particular brain regions. Such differential 
signaling m ay be associated with specific neurochem ical, 
physiological, and behavioral responses and has been proposed  
in the context o f drug discovery at a variety o f receptor  
subtypes as a strategy  to  achieve superior th erapeu tic  
outcom es.9- 11
In the case o f 5 -H T 1A receptors, an im portant advance was 
the discovery o f a first highly selective biased agonist, N L X -1 0 1  
(aka F 1 5 5 9 9 , 1 ) , which shows a m arked preference for E R K 1 /  
2  phosphorylation versus other signaling pathways ( Figure
1 ) . 12,13 1  displayed a strikingly superior activity profile in a
Figure 1. Selective 5-H T 1A receptor-biased agonists.
variety o f electrophysiology, microdialysis, behavior, and brain  
im aging studies, as com pared  to older, canonical 5 -H T 1A 
recep to r agonists.14- 16 In particular, 1 exhibited highly  
p rom isin g  p ro p erties  in m od els o f  an tid ep ressan t and  
procognitive activity as well as in m odels o f respiratory deficits 
in R ett syndrom e, an orphan disorder.17,18 T h e discovery o f 1 
therefore opened the w ay for drug discovery o f novel, selective  
biased agonists that target 5 -H T 1A receptors in specific brain  
areas th at co n tro l C N S functions and th at con stitu te , 
potentially, m ore efficacious and safer pharm acotherapeutics.
H ow ever, despite its broad pharm acological characterization,
1  rem ained isolated as a single example o f a biased agonist with  
a superior pharm acological profile but with no m edicinal 
chem istry data allowing for rational design o f other function­
ally selective 5 -H T 1A receptor agonists. In this context, our 
previous w ork investigated the stru ctu re-activ ity  relationship  
(SA R ) and structure functional activity relationships (SFA R s) 
o f novel analogues designed based on the structure o f 1 .13 In 
that study, we identified a new, patentable, and synthetically  
versatile ch em otyp e o f  selective 5 -H T 1A receptor-b iased  
agonists that preferentially activate E R K 1 /2  phosphorylation  
in vitro and show potent antidepressant-like properties in vivo. 
T h ese findings m et our objectives but did n ot identify 
structures that m ay exhibit other biased agonist profiles, 
notably for fi-arrestin recruitm ent, which, as m entioned above, 
is a m ajor target for G protein coupled receptor (G P C R )  
-biased agonist studies.
T h e present study builds upon the conclusion that the  
pyridine-2 -oxy- or phenoxy-ethyl or derivatives o f  1 - ( 1 - 
benzoylpiperidin-4-yl)m ethanam ine, represented by lead struc­
tures 2  (N L X -2 0 4 )  and 3 (N L X -2 1 9 ) , are the m ost prom ising  
chem otypes for obtaining new selective full agonists o f the
5 -H T 1A receptor ( Figure 1 ). As our previous w ork studied  
various unsubstituted derivatives, we focused herein  on  
determ ining the influence o f the substitution pattern  at the  
phenyl ring. Based on m olecular m odeling studies, we observed  
that phenyl m oiety binds in the part o f the receptor that is 
responsible for the stabilization o f various bioactive co n ­
form ations (betw een transm em brane helices 3, 5, and 6 ) , thus 
justifying diversification o f this fragm ent to obtain biased  
agonists w ith novel profiles o f  functional selectivity . 13, 19 
Specifically, we aimed to obtain, on the one hand, agonists 
with higher levels o f bias for specific signaling pathways 
(notably p E R K 1 /2 )  and, on the other hand, agonists exhibiting 
bias for signaling pathways other than p E R K 1 /2  (notably fi- 
arrestin recru itm en t). Such biased agonists with diversified 
functional profiles could prove to be beneficial for different 
C N S disorders involving serotonergic dysregulation. A  series o f  
variously  su bstitu ted  p hen oxyethyl derivatives o f  1 - ( 1 - 
benzoylpiperidin-4 -yl)m ethanam ine was therefore synthesized  
and extensively tested  in a stepwise m anner to  yield novel, 
selective, and functionally diversified 5 -H T 1A receptor agonists. 
As well as broadening our knowledge about the pharm acology  
o f 5 -H T 1A receptors, such com p oun ds could  con stitu te  
prom ising candidates for treatm ent o f different disorders 
involving serotonergic neurotransm ission, som e o f which (such  
as depression) m ay be anticipated to  respond to  p E R K 1 /2 -  
biased agonists, w hereas others m ay be b etter treated with fi- 
arrestin-biased agonists. Overall, the availability o f novel 
com pounds differentially targeting these key signaling m ech ­
anisms raises the p rospect o f achieving increased therapeutic 
efficacy with reduced side effects in the treatm ent o f C N S  
disorders.
■  R E SU L T S  A N D  D ISC U SSIO N
D e sig n  o f  a  N ov el S e rie s  o f  V a rio u s ly  S u b s ti tu te d  
P h e n o x y e th y l  D e riv a tiv e s  o f  1 - (1 -B e n z o y lp ip e r id in -4 -  
y l)m e th a n a m in e . In the present study, we decided to use 
com pound 3, a previously described unsubstituted phenox- 
yethyl derivative o f 1 - ( 1 -benzoylpiperidin-4 -yl)m ethanam ine, 
as a lead structure for m odifications. T h e previously assessed in 
silico developability m easures for com pound 3, namely, C N S  
M P O  = 4 .8 9 , L E L P  = 6 .7  and Fsp3 = 0 .3 8 , w ere considered  
favorable . 13 H ow ever, to  further confirm  the properties o f this 
com pound as a good lead structure, som e in vitro studies were 
applied. T h ey  included m etabolic stability using rat liver 
m icrosom es (R L M s), m em brane perm eability using parallel 
artificial m em brane perm eability assay (P A M P A ), hepatotox- 
icity on H ep G 2 cell line, as well as extended selectivity study  
on a m ultitarget panel, including 4 5  receptors (for the sake o f  
co m p ariso n  b etw een  th e  lead stru ctu re  and the m o st  
interesting derivatives developed within the present study, 
the abovem entioned data for these com pounds are collected in 
Table 7  and C hart 1 as well as Supporting Inform ation Table  
S 3 ). C om pound 3 showed acceptable m etabolic stability, high 
perm eability, very  low  p otential for hepatotoxicity , and 
significant (a t least 5 0 0 x )  selectivity versus the off-targets, 
including the h ER G  channel, thus proving to  be a good starting  
point for further modifications. T h e structural diversification 
was focused on introducing various substituents to  the
1 0 9 4 7 https://dx.doi.org/10.1021/acs.jmedchem.0c00814
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C h a rt 1. G rap hical V isualization  o f  S electivity  Profiles o f  C o m p o u n d s 3 , 4 4 , an d  5 6 a
“For the sake of clarity, 34  most important targets are shown out of 46  tested. The p K  values shown were estimated based on screening data and 
rounded to the nearest half-log value. For full selectivity data, see Supporting Information Tables S4 and S5. hERG p-c— hERG blockade 
determined using the patch-clamp method.
phenoxy m oiety in order to m odulate the functional profile 
while maintaining favorable developability. T h e  choice of 
substituents was controlled  primarily by m olecular weight, 
num ber of hydrogen bond donors and lipophilicity, as well as 
synthetic feasibility o f the final m olecules. As a result, a set of 
3 0  novel com pounds was proposed for chem ical synthesis and 
pharm acological evaluation.
S y n th e s is . T o  prepare the target com pounds 2 8 - 5 7 ,  we 
have utilized a m eth od  that we have previously used and 
described ( Schem e 1 ) . 13 T h e m eth od  is based on a reaction of  
reductive am ination betw een cyanohydrins 4  or 5  and the  
appropriate amines ( 6 - 2 6 ) .  Briefly, cyanohydrines 4  and 5  
w ere prepared in D arzens reaction  from  benzoylpiperidin-4-on  
derivatives and chloroacetonitrile, followed by a regioselective 
ring opening with poly(hydrogen fluoride)pyridine. A m ines
6 - 2 6  w ere p rep ared  from  the co rresp on d in g  phenols  
according to  two synthetic pathways depicted in Schem e 2 .
A m ines 6 - 2 3  were synthesized according to  a three-step  
procedure starting with W illiam son reaction 20 using appro­
priate phenols and 1,2-d ibrom oethan e. T h e  obtained 2- 
b rom oeth oxy derivatives (I  6 - 2 3 )  w ere used in Gabriel's
synthesis ,2 leading to  the desired prim ary amines. Syn­
thesis o f  amine 1 7  (R  = 3 - N H - C H 3) required additional B oc- 
p rotection  to prevent reductive am ination at a secondary  
amine group. D eprotection  o f the amine was perform ed at the 
last step o f  the synthesis o f com pound 4 5  ( Schem e 1) . Am ines 
2 4 - 2 6  w ere obtained in M itsunobu reaction 24,2S o f 2- 
(m ethylam ino)phenol with ferf-butyl-2 -hydroxyethyl carba­
m ate ( I I  2 4 )  and quinolin-8 -ol or 1H -indol-4-ol with 2 - (2 -  
hydroxyethyl)isoindoline-1,3-dione (I I  2 5  and II  2 6 ) .  T he  
following B oc-d eprotection  or methylam inolysis provided the 
desired amines. F o r  a detailed description o f the synthetic  
procedures used in the synthesis on am ines, see the Supporting  
Inform ation.
T h e final reaction  o f  reductive am ination was carried out in 
the presence o f  1 ,4-d iazab icy clo [2 .2 .2 ]o ctan e (D A B C O ) as a 
base, sodium  cyanoborohydride (N a C N B H 3) as a reducing  
agent, and with addition o f  iron sulfate heptahydrate (F e S O 4 X  
7 H 2O ) that com plexes cyanide ions and therefore contributes  
to  the im provem ent o f the reaction  yields. In an additional 
step, indole derivative 5 6  was reduced to  indoline analogue 5 7 .
S tru c tu re -A ffin ity  R e la tio n s h ip s . 5 -H T 1A R e c e p to r A f­
finity. All the obtained com pounds w ere subjected to  affinity 
determ ination using radioligand binding studies. T h e affinity of
1 0 9 4 8 https://dx.doi.org/10.1021/acs.jmedchem.0c00814
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S ch em e 1. Synthesis o f  1 -(l-B e n z o y l-4 -flu o ro p ip e rid in -4 -y l)m e th a n a m in e  D erivatives^
"Reagents and conditions: (i) DABCO, NaCNBH3, FeSO4 X 7H 2O, molecular sieves, MeOH, r.t., 3 6 - 7 2  h, yield: 18 -8 2 % ; (ii) 1.0 M HCl in 
EtOAc, r.t., 24 h, yield: 48%; (iii) CH 3COOH, NaCNBH3, 15 °C — 15 min, then r.t— 1 h, yield: 67%. X  = F or Cl.
Sch em e 2 . Synthesis o f  th e  A m in e In term ed iates  ( 6 - 2 6 )
"Reagents and conditions: (i) for compounds II 2 4 - 2 6 ,  tert-butyl-2-hydroxyethyl carbamate or 2-(2-hydroxyethyl)isoindoline-1,3-dion, PPh3, 
DIAD, TH F, 0 °C then r.t, 24 h, and 50 °C, 24 h; (ii) 1,2-dibromoethane, K2CO3, acetone, 4 0 - 8 0  °C, 2 4 - 7 2  h; (iii) for compounds II 6 - 1 6 ,  18 ­
23, potassium phthalimide, 18-crown-6 ether, DMF, 50 °C, 3 h; (iv) NaH, CH 3I, TH F, 0 °C, 30 min, then r.t, 1 h; for compound II 17 (iv) and 
then (iii); (v) for compounds 6 - 2 3 ,  25, 26, 40% M eNH2(aq), 10% NaOH, 50 °C, 2 h, then r.t., 1 h. (vi) For compound 24, 1.0 M HCl in EtOAc, 
r.t, 24 h; R1 = phthalimide or tert-butyl carbamate.
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the com pounds at 5 -H T 1A receptors was generally high, with  
p K  values ranging from  8 .1 8  to  1 2 .8 0  ( Tables 1 and 2 ). T o  
determ ine the influence o f various phenyl ring substitutions on  
affinity and exclude the contribution o f lipophilicity, we 
prim arily focused on analyzing changes o f ligand-lipophilicity 
efficiency (L L E ) , calculated as the difference betw een pK i and 
C lo gD 74 . All the relationships w ere co m p ared  to  the  
unsubstituted phenoxy derivative 3 (L L E  7 .5 9 ) , which was 
the lead structure for this series ( Figure 5 ).
First, we focused on checking the effect o f the substitution  
site on the phenyl ring using three com m only  used substituents 
(F , Cl, or O C H 3). T h e substitution in the ortho position  
increased the binding affinity; how ever, the effect was rather 
m odest and did n ot exceed 0 .5  L L E  units. T h e effect o f  
substitution in the m eta position was diversified, ranging from  
slight increase o f affinity for fluoro and m ethoxy analogues to  
decrease in the case o f the chloro derivative. O n the other  
hand, substitution in the para position generally decreased the  
affinity by up to 2  L L E  units. T h e negative effect o f a para
1 0 9 4 9 https://dx.doi.org/10.1021/acs.jmedchem.0c00814
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T ab le  1. In flu ence o f  th e  Substituen t P o sitio n  in th e  P h en yl R ing  on  5 -H T 1A R e ce p to r A ffinity and Selectivity  fo r th e  M o st  



























Ar 5-HT1Abe OLi'f D2d'9 Cl0gD7.4/l LLE'
10.21 ± 0 .2 0 6.29 ± 0 .1 3 < 6 .0 0 2.62 7.59
10.80 ± 0 .1 5 < 6 .0 0 < 6 .0 0 2.81 7.99
10.78 ± 0 .1 8 < 6 .0 0 < 6 .0 0 2.78 8.00
10.69 ± 0.25 6.20  ± 0.06* < 6 .0 0 3.24 7.45
10.10 ± 0 .1 5 < 6 .0 0 < 6 .0 0 2.76 7.34
10.89 ± 0.22 < 6 .0 0 < 6 .0 0 3.25 7.64
10.32 ± 0 .2 5 < 6 .0 0 < 6 .0 0 3.23 7.08
10.60 ± 0 .1 7 < 6 .0 0 < 6 .0 0 3.70 6.90
8.41  ± 0 .08 < 6 .0 0 < 6 .0 0 3.23 5.19
10.51 ± 0.09 7 .18  ± 0 .29* 6.17 ± 0 .0 9 2.49 8.02
9.42  ± 0 .01 7.34  ± 0 .11* 6.47 ± 0 .1 0 2.95 6.48
10.22 ± 0 .2 1 < 6 .0 0 < 6 .0 0 2.47 7.75
10.50 ± 0.20 < 6 .0 0 < 6 .0 0 2.93 7.57
8 .18  ± 0 .0 9 < 6 .0 0 < 6 .0 0 2.45 5.73
8.91  ± 0 .04 < 6 .0 0 < 6 .0 0 2.91 6.00
1 8 .66  ± 0 .07 < 6 .0 0 < 6 .0 0 2.29 6.37
(±)8-OH-DPAT 9.09 ± 0.03 NT' NT 1.47 7.68
Buspirone 8 .30  ± 0.05 NT NT 1.35 6.95
"All binding affinity values are represented as pKi (i.e., - lo g  Ki) and expressed as means ±  SEM from at least three experiments performed in 
duplicate, unless otherwise indicated; radioligand binding was performed using bCHO-K1 cells transfected with 5-H T 1A receptors. cRat cortex. 
dCHO-K1 cells transfected with D2 receptors; receptor affinity values were determined by competition binding using e[3H ]8-OH-DPAT. f [3H ]- 
prazosin and g [3H]-methylspiperone. In these conditions, pKi of phentolamine at a 1 receptors was 7.95 and pKi of haloperidol at D2 receptors was 
8.85. hCalculated distribution coefficient at pH 7.4. iLLE referring to the 5-H T 1A receptor. jNot tested *pKi value was expressed as mean ±  range 
from two experiments performed in duplicate.
substituent depended on its size, being the least pronounced  
for the 4-fluoro derivative (L L E  7 .3 4  for 3 1 )  through 4- 
m ethoxy derivative (L L E  5 .7 3  for 4 0 ) ,  to reach the lowest 
value in the case o f the 4-chloro  substituent (L L E  5 .1 9  for 3 5 ) .
In support o f the observed SARs, docking studies showed  
that, in the group o f the derivatives with m ethoxy substituent 
(3 6 , 3 8 , 4 0 ) ,  b oth  ortho- and m eta-substituted com pounds  
took  alm ost the sam e position in the binding site ( Figure 2A ). 
O n the other hand, the para-substituted analogue ( 4 0 )  was 
unable to  adopt such a position ( Figure 2 B ) probably because  
o f being too  sterically hindered in the area adjacent to the helix 
6 . In contrast to the above, all the com pounds with a smaller 
fluorine substituent (2 8 , 2 9 , 3 1 )  showed a com m on  binding
m ode ( Figure 3 ). T hese results support the conclusion from  
the binding studies that the affinity o f  para-substituted  
derivatives depends on the size o f substituent (th e smaller 
the substituent, the higher the affinity). T hese SARs are 
consistent with those established for the long-chain arylpiper- 
azines, which suggests a similar binding m o d e .26
Furth er studies focused on exploration o f different types o f  
substituents in m eta and ortho positions (well tolerated  by the 
recep to r) as well as various benzo-fused h eteroarom atic  
m oieties, which can be also considered as a kind o f ortho— 
m eta-substituted derivatives at the phenyl ring ( Table 2 ). All 
the ligands achieved very high 5 -H T 1A receptor affinity, with
https://dx.doi.org/10.1021/acs.jmedchem.0c00814
J. Med. Chem. 2020, 63, 10946—10971
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T ab le  2 . In flu ence o f  th e  T yp e o f  Substituen t in  th e  P h en yl R ing o n  5 -H T 1A R e ce p to r A ffinity and Selectivity  fo r th e  M o st 
Im p o rta n t O ff-T argets
receptor affinity0 (pKj)
Compd X Ar 5-HTV OLl'} P2d'9 ClogP 7Ah LLE'





















< 6.00 1.51 8.71
< 6.00 1.49 9.05
< 6.00 2.08 7.86
< 6.00 2.09 8.38
< 6.00 2.72 6.79
< 6.00 1.86 8.21
< 6.00 2.33 7.95
< 6.00 3.13 6.72
9 .5 6 1 0 .0 2  < 6 .0 0  < 6 .0 0  3.51 6.05
1 0 .2 2 1 0 .2 5  6 .7 6 1 0 .0 3 *  < 6.00 2.82 7.40
9 .3 7 1 0 .0 3  6 .6 9 1 0 .0 7  6 .3 6 1 0 .1 4  3.28 6.09
2.17 7.69
10.22  1 0.21  < 6.00
10.53 1 0 .24  < 6.00
9 .9 3 1 0 .2 2  6 .0 4 1 0 .0 1
10.47 1 0.19 < 6.00
9 .5 2 1 0 .1 5  < 6 .0 0
10.08 1 0.13 < 6.00
10.27 1 0.21 < 6.00
9 .8 5 1 0 .2 3  < 6 .0 0
9 .8 6 1 0 .1 1  6 .7 2 1 0 .1 3 < 6.00
54 9 .7 1 1 0 .1 2  6 .7 1 1 0 .0 2  6 .0 4 1 0 .1 2  2.63 7.08
55 1 1 .0 7 1 0 .0 6  7 .7 6 1 0 .3 2  7 .5 4 1 0 .1 2 3.22 7.85
56
57
1 2 .8 0 1 0 .1 6  7 .0 0 1 0 .0 5  < 6 .0 0  2.74 10.06
1 0 .3 5 1 0 .0 2  6 .3 6 1 0 .0 2  < 6 .0 0  2.12 8.23
aAll binding affinity values are represented as pKi (i.e., —logKi) and expressed as means ±  SEM from at least three experiments performed in 
duplicate, unless otherwise indicated; radioligand binding was performed using bCHO-K1 cells transfected with 5-H T 1A receptors. cRat cortex. 
dCHO-K1 cells transfected with D2 receptors; receptor affinity values were determined by competition binding using e[3H ]8-OH-DPAT. f [3H ]- 
prazosin and g [3H]-methylspiperone. In these conditions, pKi of phentolamine at a 1 receptors was 7.95, and pKi of haloperidol at D2 receptors was 
8.85. ^Calculated distribution coefficient at pH 7.4. iLLE referring to the 5-H T 1A receptor. * pKi value was expressed as mean ±  range from two 
experiments performed in duplicate.
subnanom olar or even picom olar K i values and generally very  
high L L E  values.
T h e m ost pronounced  increase in 5 -H T 1A receptor affinity 
was noted  in the case of derivatives containing H -b ond  donor 
(H B D ) m oiety at the m eta position (4 5 , 4 7 , 5 6 , and 5 7 ) .  
W o rth  m entioning is the fact that one of the m eta-H B D  
derivatives, com pound 5 6 , had an exceptionally high affinity, 
reaching subpicom olar values (pK i 12 .80 , K i 0 .1 6  pM , L L E
1 0 .0 6 ) . T h e increase in binding affinity o f the derivatives with  
H B D  in the m eta position can be explained by their ability to  
create an additional hydrogen bond with serine S er5 .4 2  in the  
binding site o f the 5 -H T 1A receptor ( Figure 4 ) . This stabilizes 
the ligand—receptor com plex and lowers the binding energy  
(IF D  score for com pound 5 6  = —4 6 5 .2 6  com pared to —4 6 3 .6 9  
for com pound 3 ) .
T h e hypothesis that creating a hydrogen bond in this region  
im proves binding affinity was further supported by the marked  
increase in L L E  for the benzam ide derivatives ( 4 2  and 4 3 ) ,  
which are also capable of form ing this interaction. M oreover, 
the m eta derivatives n ot capable o f form ing H -bonds (4 6 , 4 9 ,  
5 0 )  displayed low er affinity, which is consistent with the  
observation m ade for com pound 3 3  (a  m eta-chloro derivative) 
and suggests that they exert a negative steric contribution (this 
was, how ever, less pronounced  than in the case o f the para  
analogues).
Regarding the substitution at the benzoyl m oiety, the 4-  
chloro analogues had overall low er L L E  than their 4-fluoro  
counterparts, suggesting that this m odification is n ot generally 
favorable.
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Figure 2. Predicted binding mode of the methoxy derivatives, that is, compound 36 (light teal) together with 38 (pink) (A) and compound 40  
(gray) (B ) in the site of the serotonin 5 -H T ^  receptor. Amino acid residues engaged in ligand binding (within 4  A from the ligand atoms) are 
displayed as sticks, whereas crucial residues, for example, forming H-bonds (dotted yellow lines), n - n /C H - n  stacking (dotted cyan lines), and 
cation—n  interactions (dotted green line) are represented as thick sticks. EC L2 residues were hidden for clarity; E C L — extracellular loop. The 
homology model of the 5 -H T ^  receptor is based on the crystal structure of the 5-H T ^  receptor (PDB ID: 4IAR).
Figure 3. Predicted binding mode of the fluoro derivatives, that is, 
compound 28 (yellow) together with 29 (pink) and 31 (green) in the 
site of the serotonin 5 -H T ^  receptor. Amino acid residues engaged in 
ligand binding (within 4  A from the ligand atoms) are displayed as 
sticks, whereas crucial residues, for example, forming H-bonds (dotted 
yellow lines), n—n /C H —n stacking (dotted cyan lines), and cation—n  
interactions (dotted green line) are represented as thick sticks. EC L2  
residues were hidden for clarity; E C L — extracellular loop. The 
homology model of the 5 -H T ^  receptor is based on the crystal 
structure of the 5-H T ^  receptor (PDB ID: 4IAR).
Selectivity  v ersu s K ey A n tita rgets , th e  A d re n e rg ic  a 1 a n d  
D o p a m in e rg ic  D 2  R ece p to rs . P revious studies o f  1 -(1 -  
benzoylpiperidin-4-yl)m ethanam ine derivatives indicated that 
the highest risk o f  off-target interactions is with adrenergic a i  
and dopam inergic D 2 recep tors .13,27—29 A ccordingly, all the  
novel com pounds were tested  for binding to  these receptors to  
confirm  their selectivity ( Tables 1 and 2 ).
C o n cern in g  a 1 rece p to r affinity, the m ajority  o f  the  
com pounds showed very high selectivity for 5 -H T 1A over a 1 
and D 2 receptors (over 1 0 0 0 —1 0 ,0 0 0  tim es). In general, 
increased affinity for the a 1 receptor was observed for the  
ortho-substituted analogues (3 6 , 3 7 , 4 4 ) .  T h e highest affinities 
(p K  6 .6 —7 .8 )  w ere observed for the derivatives with the ortho- 
m ethoxy substituent (3 6 , 3 7 )  and their bicyclic analogues, with 
oxygen or nitrogen in the ortho position (5 1 , 5 2 , 5 3 , 5 4 , 5 5 ) .  
H igh a 1 receptor affinity was also observed for the indole 
derivative 5 6  (p K  7 .0 0 ) . Interestingly, the ortho-fluoro- and  
ortho-chloro-derivatives (2 8 , 3 2 )  did n ot show significant
Figure 4. Predicted binding mode of compound 5 6  (with HBD in 
meta position) in the site of the serotonin 5-H T 1A receptor. Amino 
acid residues engaged in ligand binding (within 4  A from the ligand 
atoms) are displayed as sticks, whereas crucial residues, for example, 
forming H-bonds (dotted yellow lines), n— n /C H —n  stacking (dotted 
cyan lines), and cation—n  interactions (dotted green line) are 
represented as thick sticks. EC L2 residues were hidden for clarity; 
E C L — extracellular loop. The homology model of the 5 -H T 1A 
receptor is based on the crystal structure of the 5-H T 1B receptor 
(PDB ID: 4IAR).
affinity for the a 1 receptor (p K  < 6 ) , indicating that halogen in 
this position impairs a 1 receptor binding. In com parison, 
literature data indicate that ortho-m ethoxy- or ortho-ethoxy- 
substitution in the aryl m oiety increase a 1 receptor affinity. F o r  
example, in the structure o f  tamsulosin, a selective a 1A receptor  
an tagonist used  for the tre a tm e n t o f  benign p ro sta tic  
hyperplasia, a 2 - ( 2 -ethoxyphenoxy)ethanam ine fragment, can  
be highlighted .30 N evertheless, it should be noted  that 
selectivity for 5 -H T 1A versus a 1 receptors was generally very  
high and was less than 1 0 0 0 X  for only two com pounds (3 7 ,  
5 2 ) .
In the case o f the D 2 receptor, only one com pound ( 5 5 )  
showed substantial affinity (p K  D 2 7 .5 4 ) . This observation is 
in line with the fact that the 2 ,2 -dim ethyl-2 ,3 -dihydro-1 - 
benzofuran m oiety was previously used in the structure o f dual 
acting, 5 -H T 1AR  ag o n ist/D 2R  antagonist ligands.31 H ow ever, 
the affinity o f  5 5  for the D 2 receptor did n ot significantly affect 
selectivity because its affinity for the 5 -H T  1A receptor was still
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Figure
due to
5. Changes in LLE in relation to unsubstituted lead structure 3 
substitution at the phenyl ring.
over 3 .5  orders o f m agnitude higher (> 3 0 0 0 X , p K  5 - H T ^  =
1 1 .0 7 ) .
Sum m ing up, m ost o f  the presented com pounds showed  
substantial selectivity versus key antitargets ( K  ratio over 
1 0 0 0 -fold) although the p hen oxyethan am in e scaffold is 
com m on  also for ligands o f  other m onoam inergic receptors. 
This supports the finding that the 1 -[4 -(am in o m eth y l)-4 -  
fluoropiperidin-1 -yl]eth an-1 -one core is the essential scaffold 
for providing b oth  high affinity and high selectivity for the  
5 -H T 1A receptor.
S tr u c tu r e -F u n c tio n a l  A c tiv ity  R e la tio n s h ip s . Based on  
the results o f  the studies described above, 2 5  com pounds were 
selected for functional studies. T h e functional profiles o f the  
novel com pounds w ere m easured at several pathways engaged  
in 5 -H T 1A receptor signal transduction. C om pounds were 
tested  in four functional assays: E R K 1 / 2  phosphorylation  
(p E R K 1 /2 ) , adenylyl cyclase inhibition (cA M P ), ^-arrestin  
recruitm ent (^-arrestin ), and calcium  mobilization (C a 2+). T o
classify the agonist efficacy o f the com pounds, we assumed that 
E max values higher than 80%  relative to  the m axim al effect of  
serotonin are characteristic o f a full agonist, betw een 7 9  and 
2 1 % o f a partial agonist, and 2 0 % or less, indicating negligible 
agonist activity. T h e experim ents were carried out using cell 
lines expressing the recom binant hum an 5 -H T 1A receptor.
In term s o f  potency, the general trends ( Tables 3 and 4 ) 
were similar to  those established in affinity studies. C om p ared  
to  3 , the derivatives substituted with the H B D  in the m eta  
position (4 3 , 4 5 , 4 7 , 4 8 )  w ere characterized by a rise in 
p oten cy  in all the signaling pathways. T h e sam e trend was 
observed for the bicyclic analogues (5 1 , 5 5 , 5 6 , 5 7 ) ,  but the 
oth er derivatives show ed m o stly  d ecreased  p o te n cy  in 
functional assays. T h e notable exceptions w ere com pound 3 6  
and 3 8 , the ortho- and m eta-m ethoxy analogues, respectively, 
which were characterized by generally higher p oten cy  than 3  as 
well as com pound 4 2 , an orfho-carboxam ido analogue, which  
displayed p oten cy  similar to  3, with m odest variations in both  
sides. T h e extent o f  p oten cy  change varied betw een individual 
analogues in term s o f  signaling pathw ays, resulting in 
diversified functional selectivity profiles for som e o f  them .
T h e efficacy o f  the ligands for the E R K 1 /2 , cA M P, and fi- 
arrestin pathways was generally high, falling slightly below  80%  
in only a few cases. T h e vast m ajority o f  the com pounds can  
therefore be considered as full agonists in those signaling 
pathways. O n  the other hand, m ost o f the com pounds showed  
low er efficacies in the calcium  mobilization assay. T hirteen  
com pounds were classified as partial agonists and two even as 
negligibly active, as they showed marginal level o f stim ulation  
(1 5 % ). B oth  these com pounds were para-substituted analogues 
(3 5  and 4 0 ) .
B ias  F a c to r s .  T h e functional selectivity o f the ligands was 
analyzed by calculating bias factors. T hese com pare the efficacy 
and p oten cy  o f  com pounds for pairs o f  signaling pathways 
using the following equation32- 35




E maxpath1 X  E C 50-path2
E C 50-path1 X  Emaxpath2 z
lig
E m a x path1 X  E C 5 0 - p a t h 2
E C 50-path1 X  E maxpath2
ref
T h e calculations in the p resent study follow the same 
approach as in our previous study .13  Briefly, the bias factor 
provides a m easure that integrates E max and E C 50 values o f  both  
a test ligand and a reference com pound (i.e. serotonin ). Results 
are presented in Tables 5 and 6  and com pounds which  
displayed th at a significant bias (over 1  log) was highlighted in 
green (for positive values) or in blue (for negative values). 
T h ose com pounds which showed significant bias, b u t with low  
p E C 50 values, were m arked in gray.
E R K 1/2  v e rs u s  cA M P . M o st o f  the com pounds showed a 
preference for E R K 1 /2  phosphorylation, with the highest bias 
factors (> 1  log) being found for com pounds 4 0 , 4 4 , and 5 5 . 
T h e highest E R K 1 /2  phosphorylation preference was found 
for com pound 5 5  with a bias factor o f  2 .8  log. Three  
com pounds (4 7 , 4 8 , and 5 1  ) , preferred the cA M P pathway
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ERKl/2fc cAMP* p-arrestinc Ca2+b
E m a x  pECso E m ax  pECso E m  a x  pECso E m ax  pECso
92% 9.10 90% 8.09 96% 7.98 91% 7.20
95% 8.24 89% 7.74 97% 7.61* 90% 6.82*
96% 8.64 99% 7.80 91% 7.46 73% 7.16*
93% 7.70 89% 7.40 104% 6.21* 90% 6.19*
98% 8.24 96% 7.37 99% 7.06* 73% 7.00
NTd NTd 87% 7.59 94% 7.76 36% 6.26*
97% 7.99 88% 7.71 99% 6.65* 80% 6.60*
88% 6.93 63% 6.32 109% 6.01* 15% 5.28
NTd NTd 83% 9.86* 90% 9.43 54% 9.52*
97% 9.40 89% 8.98 90% 8.64* 64% 7.15
95% 8.14 96% 7.69 95% 6.91 74% 6.50
86% 7.68 88% 6.25 82% 5.79 15% 6.21
78% 7.32 59% 6.48 65% 5.60 24% 5.88*
1 100% 8.33 92% 7.22 98% 6.71 66% 6.52
(±) 8-OH-DPAT 93% 8.09 63% 7.50 101% 7.84 35% 7.66
Buspirone 44% 7.82 49% 7.14 100% 6.73 8.3% 7.42*
Serotonine 100% 7.48 100% 7.51 100% 6.89 100% 7.23
“All the functional activity values were expressed as means from at least three experiments performed in duplicate, unless otherwise indicated. For 
the sake of clarity, the SEM values were omitted in this table and are presented in the Supporting Information— Table S1; the functional assay was 
performed using bCHO-K1 cells. cU2OS cells (Tango LiveBLAzer assay kit). dN T — not tested; * value was expressed as mean from two 
experiments performed in duplicate. eData for Serotonin on ERK, cAMP, and fi-arrestin are reproduced from the previous paper.13
and significant bias was observed for com pound 4 7  (bias factor 
- 1 . 0 3 ) .
W h en  com paring 3-chloro-4-fluorobenzoyl derivatives (2 9 ,  
3 8 , 4 0 , 4 7 )  with their 3,4-dichlorobenzoyl derivative cou nter­
parts (3 0 , 3 9 , 4 1 , 4 8 ) ,  it is noticeable that the form er always 
show a m ore pronounced  biased profile than the latter 
com pounds.
E R K 1/2  v e rs u s  f i-A rre s tin . T h ree com pounds preferred  
E R K 1 /2  phosphorylation versus fi-arrestin, and four co m ­
pounds preferred  fi-arrestin  recru itm en t versus E R K 1 /2  
phosphorylation. This is the first tim e, to  our knowledge, 
that fi-arrestin-biased agonists have been reported  for the  
selective 5 -H T 1A receptor ligands. Bias factors for the E R K 1 /2 -  
biased agonists ranged from  1.21 for com pound 4 1  to 1 .43  for
com pound 4 4 , w hereas in the case o f  fi-arrestin-biased  
agonists, their bias factors w ere m uch m ore pronounced  
(from  - 1 . 9 5  for 4 8  to  - 3 .7 1  log for 5 6 ) .
T h e E R K 1/2-p referrin g  com pounds w ere the p ara-m ethoxy  
derivatives ( 4 0  and 4 1 )  and the ortho--methylamine derivative 
4 4 . O n the other hand, the com pounds that showed bias for fi- 
arrestin  recru itm e n t w ere eith er th e  b icy clic  a ro m atic  
derivatives (5 1  and 5 6 )  or m eta-acetam ido derivatives (4 7  
and 4 8 ) .
It is noticeable that the ortho-m ethylam ine-substituted  
derivative ( 4 4 )  showed substantial E R K 1 /2  bias (1 .4 3 ) ,  
while the m eta-m ethylam ine-su bstitu ted  derivative ( 4 5 )  
showed an opposite preference (bias factor - 0 . 6 0 ) .
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ERKl/2fa cAMPfa (3-arrestinc Ca2+fa
f m a x  pECso f m ax pECso F m a x  pECso F m a x  pECso
92% 9 .10  90% 8 .09  96% 7.98  91% 7.20
92% 8 .68  95% 8 .22  101% 8.08* 84% 7.53
87% 9 .74  92% 9 .18  101% 8.55  105% 7.42*
89% 8 .86 77% 7.82 96% 6.79 43% 6.99*
83% 10.13 87% 9.95 100% 10.05 94% 7.49
87% 8 .22 91% 7 .77 101% 7.22 82% 6.86*
102% 9.75 89% 10.86* 93% 12.68 100% 7.66*
100% 9.23 94% 10.18 96% 10.60* 100% 7.36*
93% 8 .72 82% 7 .83 98% 7.27* 59% 6.83
100% 7.25 99% 6 .56 104% 6.14* 73% 6.14
96% 9 .30 104% 9 .47 92% 11.83* 67% 7.87
81% 10.99 88% 8 .18 99% 9.49 89% 7.27*
102% 10.53 96% 10.06 94% 13.67 79% 7.84
94% 11.44 89% 10.88 92% 11.29 56% 8.45*
aAll the functional activity values were expressed as means from at least three experiments performed in duplicate, unless otherwise indicated. For 
the sake of clarity, the SEM values were omitted in this table and are presented in the Supporting Information— Table S1; the functional assay was 
performed using bCHO-K1 cells. cU2OS cells (Tango LiveBLAzer assay kit); * value was expressed as mean from two experiments performed in 
duplicate.
E R K 1/2  v e r s u s  C a 2+. In general, m ost o f the com pounds  
showed substantial bias for E R K 1 /2  phosphorylation versus 
calciu m  m ob ilizatio n  ( C a 2+) and n on e o f  th e  te ste d  
com pounds showed preference for C a2+. T h e highest E R K 1 /  
2  preference was found for the benzo-fused, five-m em bered  
ring derivatives ( 5 5 - 5 7 ) ,  reaching a bias factor o f 3 .4 2  for 
com pound 5 5 .
cA M P  v e r s u s  ^ -A r re s t in . Only five com pounds (3 0 , 3 3 , 
3 9 , 4 1 ,  4 4 )  exhibited  som e p referen ce  tow ard  cA M P  
inhibition, how ever not exceeding half a log, w hereas the rest 
o f the com pounds preferred fi-arrestin recruitm ent. As seen for 
E R K 1 /2  versus cA M P bias, a favorable influence o f the 3 ,4 -  
dichlorobenzoyl m oiety on cA M P p oten cy was observed here, 
as com pared to  the corresponding 3-chloro-4-fluorobenzoyl 
analogues.
A m ong the derivatives with m arked fi-arrestin recruitm ent 
bias, com pounds 4 7 , 4 8 , 5 1 , and 5 6  w ere identified again, as in 
th e  case o f  p referen ce  for fi-arrestin  versus E R K 1 /2 .  
Interestingly, com pound 5 5  also preferred fi-arrestin pathway  
versus cA M P, although previously it exhibited the highest 
preference for E R K 1 /2  versus fi-arrestin. This is due to its very
high p oten cy  in the E R K 1 /2  assay (p E C 50 1 0 .9 9 )  and also 
relatively high fi-arrestin p oten cy  (p E C 50 9 .4 9 ) , as com pared to  
other assays, w here its p oten cy  was noticeably weaker.
Overall, it should be noted that preference tow ard fi-arrestin  
recruitm ent was m uch higher than for the m ost biased  
reference com pound, ( ± )  8 -O H -D P A T  ( - 1 . 1 8 ) ,  and reached  
an extrem ely high value ( - 4 . 2 4 )  for com pound 5 6 .
Previous studies by S troth  and co-w orkers are w orth  
m entioning, w here the authors identified 5 -H T 1A-biased  
ligands with a strong preference for cA M P over fi-arrestin  
signalin g .36 H o w ev er, it sh ould  be n o te d  th a t th o se  
arylpiperazine derivatives had only partial agonist properties 
in the cA M P assay ( 5 3 - 7 3 % ) .  T h ey  also showed very low  E max 
values in the fi-arrestin assay ( 6 - 3 6 % ) .  N otew orthily, Stroth et 
al. reported  that the reference agonist ( ± )  8 -O H -D P A T  
achieved only 44%  efficacy in the fi-arrestin assay, while herein  
it reached 1 0 1 %, so the observed differences in signaling bias 
m ay be at least partially due to the m ethodological differences 
(fi-arrestin assay in that study was perform ed using Path- 
H un ter eXpress H T R 1 A  C H O -K 1 fi-Arrestin G P C R  Assay
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T ab le  5 . B ias F a c to rs  o f  C o m p o u n d s ( 2 8 —3 3 , 3 5 , 3 6 , 3 8 —4 1 )  and  R eferen ces at 5 -H T 1A R e ce p to rs
5-HTia receptor bias factor (logarithmic value)
ERK1/2 vs. ERK1/2 vs. ERK1/2 cAMPvs. cAMP p-arrestin







1.05 0.51 1.65 -0.54 0.60
0.56 0.03 1.19 -0.53 0.63 1.16
0.85 0.60 1.35 -0.25 0.50 0.75
0.35 0.85 1.27 0.50 0.92 0.42
0.90 0.57 1.11 -0.33 0.20 0.54
_ a _ a _ 0 -0.83 1.42 2.25
0.35 0.73 1.22 0.38 0.86 0.48
0.78 0.23 2.15 -0.55 1.38 1.92
-■ -■ -■ -0.23 0.24 0.47
0.49 0.19 2.17 -0.30 1.68 1.98
0.48 0.63 1.49 0.15 1.02 0.87
1.44 1.31 1.98 -0.13 0.54 0.67
1.00 1.21 1.70 0.21 0.70 0.49
1 1.17 1.02 1.76 -0.15 0.59 0.74
(±) 8-OH-DPAT 0.79 -0.39 0.59 -1.18 -0.20 0.98
Buspirone 0.66 0.14 0.86 -0.52 0.21 0.73
5-HT 0.00 0.00 0.00 0.00 0.00 0.00
aNo data for pERK assay. Compounds that displayed a significant bias (over 1 log) are highlighted in green (for positive values) or in blue (for 
negative values). Those compounds that showed significant bias but with low pEC50 values are marked in gray.
D iscoveR x and in the current study using T ango H T R 1A -bla  
U 2O S  LiveBLA zer assay kit, Life T echn ologies).
cA M P  v e r s u s  C a 2+. Eleven com pounds markedly preferred  
the cA M P pathw ay versus C a2+. N otew orthily, the m ost biased  
com pounds (w ith  bias factors over 2 )  had H B D  in the m eta  
position (4 5 , 4 7 , 4 8 , 5 6 , and 5 7 ) ,  further indicating the 
positive influence o f this substituent on cA M P inhibition 
p oten cy . B ecau se  o f  relatively low  p o te n cy  o f  all the  
com pounds in the calcium  mobilization assay, none o f them  
exhibited bias tow ard this signaling pathway.
^ -A r r e s t in  v e r s u s  C a 2+. T h irteen  co m p o u n d s w ere  
markedly biased for ^-arrestin. F o u r o f the com pounds (4 7 ,  
4 8 , 5 1 , and 5 6 )  showed extrem ely high bias for ^-arrestin  
(over 3 .5  log), reaching a 6 .2 5  log value (over 1 ,0 0 0 ,0 0 0  tim es) 
for co m p o u n d  5 6 . T h e  relatively low er ability o f  the  
com pounds to stim ulate C a2+ m obilization resulted in a lack  
o f noticeable C a2+-preferring biases.
"S ig n a lin g  F in g e rp r in t"  A n a ly sis . T h e functional studies 
enabled selection o f biased agonists that exhibit preference for 
specific pathways. T o  describe the pattern  o f behavior o f the 
com pounds in the different pathways, we calculated “signaling
fingerprints” based on m easures o f p oten cy  and efficacy and 
represented them  as bars o f particular height and color  
intensity (heat m ap ), respectively. T h e p oten cy o f each ligand 
in a particular assay was norm alized according  to  the  
perform ance o f the native neurotransm itter (i.e., serotonin) 
in this assay. It was calculated using the following equation:
normalized ligand potency
=  -  log
A  “signaling fingerprint” therefore allows for the simulta­
neous com parison o f a ligand’s functional profile in all 
pathways. “Signaling fingerprints” w ere calculated for b oth  
the reference and the novel com pounds, including all four 
tested  pathways, with serotonin as the native ligand and cA M P  
as the reference pathway (due to a relatively higher p oten cy  o f  
serotonin in this assay). Significant preference o f a given
i
E C 50 pathlig “
' E C   ̂E C 50 path
 ̂E C 50 ref. path y native
k ligand ̂
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Compounds that displayed a significan
5-HTia receptor bias factor (logarithmic value)
ERK1/2 ERK1/2 vs. ERK1/2 cAMPvs. cAMP P-arrestin
vs. cAMP P-arrestin vs. Ca2+ P-arrestin vs. Ca2+ vs. Ca2+
1.05 0.51 1.65 -0.54 0.60 1.15
0.47 -0.04 0.93 -0.51 0.46 0.97
0.57 0.53 1.98 -0.04 1.42 1.45
1.13 1.43 1.93 0.31 0.81 0.50
0.20 -0.60 2.33 -0.80 2.14 2.93
0.45 0.33 1.12 -0.12 0.67 0.79
-1.03 -3.49 1.85 -2.47 2.87 5.34
-0.90 -1.95 1.61 -1.06 2.50 3.56
0.97 0.83 1.84 -0.14 0.87 1.01
0.73 0.49 1.00 -0.23 0.27 0.50
-0.17 -3.11 1.33 -2.94 1.50 4.44
2.80 0.81 3.42 -1.99 0.62 2.61
0.53 -3.71 2.54 -4.24 2.02 6.25
0.61 -0.44 2.95 -0,99 2.34 3.39
bias (over 1 log) are highlighted in green (for positive values) or in blue (for negative values).
pathway was defined in this study as a difference in norm alized  
ligand p oten cy  o f at least 1 order o f m agnitude ( 1  log).
A m ong the reference com pounds ( Figure 6 ) , the m ost 
biased was com pound 1 , showing significant preference for 
E R K 1 /2  phosphorylation over all o ther assays, which is in line 
with previous studies.12,13 O n the other hand, ( ± )  8 -O H - 
D P A T  displayed a 1 log preference for the fi-arrestin versus 
cA M P pathway but was unbiased with respect to  other 
pathw ays. Buspirone, con sisten t w ith its partial agonist 
properties, showed low  efficacy in all assays but fi-arrestin, 
w hich was particularly evident for calcium  mobilization (E max 
8 .3 % ); the potencies, how ever, did not differ significantly.
T h e “signaling fingerprints” for the m ost interesting novel 
com pounds, in com parison with the lead structures 2  and 3, 
are shown in Figure 7 . In the rows, the analogues with 
structurally closest substituents w ere collected  to  show the 
gradual im pact o f their m odification on changes in the 
functional profile. T h e p E R K 1/2-p referrin g  analogues are 
shown in the left colum n, the m ore balanced in the middle, 
and the fi-arrestin-biased agonists in the right colum n.
Based on the m ore detailed analysis o f the “signaling 
fingerprints”, the novel 5 -H T 1A receptor agonists can be 
categorized into three types, divided into five subtypes, each  
with a different functional selectivity profile. Type I includes 
ligands with a significant preference for E R K 1 /2  phosphor­
ylation and a diverse profile o f activity in other assays, which is 
mainly differentiated by the level o f activation o f fi-arrestin  
recruitm ent. T ype IA, including com pounds 4 4  and 2 , consists 
o f ligands which showed significant preference for E R K 1 /2  
phosphorylation over all o th er pathways, similar to  the  
reference biased agonist, 1 . C om pounds 3 and 5 5 , which  
w ere classified into type IB, w ere characterized by a significant 
preference for E R K 1 /2  phosphorylation over cA M P and C a2+, 
but n ot fi-arrestin. T ype II includes com pounds 4 5  and 5 7 , 
w hich show a similar level o f activity in E R K 1 /2 , cA M P, and fi- 
arrestin assays, with a slight preference for the latter.
In contrast to types I and II, and o f particular interest in the 
present study, are type III com pounds: these include first-in­
class ligands that strongly prefer fi-arrestin recruitm ent over all 
other signaling pathways. It is notew orthy that such a profile 
was not observed for any o f the reference com pounds, and, to  
our knowledge, has n ot been previously described in the 
literature, which could imply that these com pounds m ay  
exhibit novel pharm acological and, potentially, therapeutic 
properties. T ype IIIA  (com pounds 5 1  and 5 6 )  includes ligands 
characterized by the strongest preference o f the fi-arrestin  
pathway, similar levels o f activity in E R K 1 /2  and cA M P assays, 
and m uch low er stim ulation o f C a2+. T ype IIIB, represented by  
com pound 4 7 , is characterized by the high levels o f activity in 
b oth  fi-arrestin and cA M P assays (with especially marked
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Figure 6 . “Signaling fingerprints” for reference compounds (bar height— normalized ligand potency in log scale, bar color— ligand efficacy, as 
percent EmJ .
activity o f fi-arrestin pathw ay) and low er ability to  activate 
E R K 1 /2  phosphorylation and calcium  m obilization. N o te ­
w orthily, com pound 4 7  was the only one that showed  
significant preference for activity (above 1 log) in the cA M P  
assay over E R K 1 /2  phosphorylation.
Sum m ing up, the following structure functional selectivity  
relationships could be inferred:
( 1 )  the presence o f  an H -bond-form ing substituent in the 
ortho position o f the phenoxyethyl m oiety  (4 4 , 5 5 )  or a 
nitrogen atom  built in the aryl ring in the sam e position  
( 2 ) decreases the ability to  activate fi-arrestin recruit­
m en t in the tested  group o f 5 -H T 1A receptor agonists, 
thus relatively enhancing a preference for E R K 1 /2  
phosphorylation.
( 2 ) substitution o f the H B D  m oiety  in the m eta position of  
the phenoxyethyl m oiety  (4 5 , 5 7 )  increases agonist 
p oten cy  in all signaling pathways, with the effect being  
especially p ronounced  for cA M P inhibition and fi- 
arrestin recruitm ent. E xcep t for calcium  mobilization  
being substantially weaker, those poten t agonists do n ot 
distinguish significantly betw een other pathways.
(3 ) in contrast, the derivatives with a bicyclic arom atic 
m oiety  ( 5 6  and 5 1 )  or a flat, n-electron-containing  
substituent (e.g. 4 7 )  exhibited particular preference for 
fi-arrestin recruitm ent, yielding very strong activity in 
this assay. N otew orthily, replacem ent o f an arom atic  
indole m oiety  o f  5 6  with a partially saturated indoline 
( 5 7 )  m arkedly decreased fi-arrestin recruitm ent, result­
ing in no particular preference over E R K 1 /2  phosphor­
ylation or cA M P inhibition, thus confirm ing this finding. 
It should be noted  that, to  our knowledge, these  
com pounds are the first 5 -H T 1A ligands to  show such a 
strong biased agonism  for fi-arrestin recruitm ent and
this, in itself, constitutes an intriguing novel finding in 
drug discovery at this receptor.
M ore  broadly, these in vitro data strongly indicate that it is 
possible to  identify specific stru ctu ral m otifs th a t are 
responsible for directing 5 -H T 1A receptor signaling to  distinct 
intracellular responses.
D e v e lo p a b ility  S tu d ie s . T h e developability o f the novel 
com pounds was initially assessed in silico using L E L P , Fsp3, 
and C N S -M P O  m easures ( T ab le S 2 ) .  M ajority  o f  the  
com pounds showed favorable score values, thus testifying to  
the overall prom ising developability potential o f the explored  
series. In order to support the choice o f  p roper candidates for 
in vivo tests, selected in vitro developability studies were  
perform ed. As a first step, the novel com pounds displaying the 
m ost interesting functional profiles w ere tested  for prelim inary  
m etabolic stability using R LM s ( Table S 3) . T h e stability was 
assessed referring to  the m arketed drugs o f  different stabilities, 
aripiprazole and verapamil, showing high or low  stability in the 
given conditions, respectively. V arious levels o f stability were 
found for the novel com pounds, ranging from  high stability for 
com pounds 4 7 , 4 8 , 5 1 , and 5 6  ( 7 3 —87% ), through m edium  
stability for com pounds 2 , 3, and 4 4  ( 5 4 —59% ), to  low  
stability for com pounds 5 5  and 5 7  (2 1  and 3 7 % ). Based on the 
functional studies and the above results, com pound 5 6 , a fi- 
arrestin  recru itm en t-b iased  agonist w ith high m etab olic  
stability, and com pound 4 4 , an E R K 1 /2  phosphorylation- 
preferring ligand with m edium  m etabolic stability, were 
selected for further studies. T o  confirm  prelim inary m etabolic 
stability data, for the lead structure 3  as well as com pounds 4 4  
and 5 6 , intrinsic clearance was determ ined in com parison with 
the reference C N S drugs aripiprazole and diazepam  ( Table 7 ). 
As expected, com pound 4 4  and the lead structure 3  showed  
the sam e level o f m edium  m etabolic stability (C L int 4 8 .8  and
1 0 9 5 8 https://dx.doi.org/10.1021/acs.jmedchem.0c00814
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Figure 7. “Signaling fingerprints” for the novel compounds (bar height— normalized ligand potency in log scale, bar color— ligand efficacy, as 
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4 1 .7  m L /m in /k g , resp ectively ), sim ilar to  diazepam , a 
reference C N S drug with m edium  but acceptable stability, 
w hereas com p ou n d  5 6  was m ore stable, w ith intrinsic  
clearance close to  aripiprazole, a reference C N S drug showing 
a very high stability in this experim ental setting ( C L int 9 .6  and
7 .2  m L /m in /k g , respectively).
As a next step, com pounds 4 4  and 5 6  were tested  for 
m em brane perm eability using P A M P A  and for potential 
h epatotoxicity  using H ep G 2 cell viability ( Table 7 ) .  Both  
com pounds, similar to the lead structure 3 , showed satisfying 
perm eability ( > 1  X  1 0 —6 c m /s ) ,  suggesting good absorption  
and brain penetration  as well as very low  hepatotoxicity, n ot 
reaching statistically significant reduction o f viability even in a 
concentration  as high as 5 0  ^M .
3 8.6 ±  1.4 >50 /¿M 41.7
44 6.7 ±  1.1 >50 /¿M 48.8
56 4.7 ±  0.4 >50 /¿M 9.6
references Caffeine Doxorubicin diazepam
15.1 ±  0.40 <1 fXM 31.0
norfloxacin CCCP aripiprazole
0.56 ±  0.13 <10 /¿M 7.02
Finally, com pounds 4 4  and 5 6  were tested  for selectivity  
against a broad group o f  4 5  off-targets, including those  
structurally and evolutionally closest to the 5 -H T 1A receptor as 
well as the m ost troublesom e for drug developm ent (e.g., 
h E R G  channel, C h art 1 , Supporting Inform ation Tables S 4  and  
S 5 ). In m ost cases, the affinity for the off-targets proved to  be 
in the m icrom olar range (< 5 0 %  binding in 1 X  1 0 -6 ) .  F o r  
som e o f the targets, binding was stronger, but considering the 
very high affinity o f the tested  com pounds for the 5 -H T 1A 
receptor, the estim ated selectivity was still over 3 orders of  
magnitude ( > 1 0 0 0 x ) ,  even relatively higher than for the lead  
structure 3 . Interestingly, com pound 5 6 , which displayed 
relatively highest affinity for som e o f  the off-targets (reaching  
p K i ~  8 ) , proved to  be also relatively the m ost selective 
(> 1 0 ,0 0 0 x )  because o f its extrem ely high affinity for the 5- 
H T 1A receptor (pKi = 1 2 .8 0 ) . Based on all the data m entioned  
above, com pounds 4 4  and 5 6  w ere ultim ately selected for in 
vivo studies.
In V ivo  S tu d ie s . So far, there is only sparse inform ation  
connecting particular signaling transduction pathways with 
physiological effects. Evidence indicates that increased cortical 
E R K 1 / 2  phosphorylation is associated with antidepressant 
activity , 37,38 w hereas inhibition o f  cA M P p rodu ction  by  
hippocam pal 5 -H T 1A receptors m ay interfere with m em ory  
process .39,40 O n the other hand, it is currently n ot known what 
physiological effects are associated with activation o f  ̂ -arrestin  
recruitm ent m ediated by 5 -H T  1A receptors. N evertheless, it is 
very im portant for drug discovery to establish a link betw een
T ab le  7 . P erm eab ility , H e p ato to xicity , an d  In trin sic  
C learan ce  o f  C o m p o u n d s 3 , 4 4 , an d  5 6
hepatotoxicity 50% intrinsic clearance 
PAMPA Pe viability of HepG2 CLM
compound [10—6 cm/s] ±  SD cells [mL/min/kg]
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C h a rt 2 . D ifferential P rofiles in the F S T  (in  B lu e) an d  L L R  (in  R ed ) o f  C o m p o u n d s 4 4  (A ) and 5 6  ( B ) ,  th e  5 -H T 1AR -B iased  
A gonists w ith  C o n trastin g  F u n ctio n al S electivity  Signaling F in g erp rin ts  (P re fe re n tia l fo r p E R K 1 /2  an d  ^ -A rrestin , 
R esp e ctiv e ly )“
*p < 0 .0 0 0 1 , *p < 0 .0 0 0 0 1 .
particular functional profiles and the desired pharm acological 
effects.4 1,42 T h erefore, tw o com pounds with significantly 
differing in vitro functional p E R K 1 /2  versus 5 -a rre stin  
selectivity profiles were com pared in various in vivo measures  
relevant to  5 -H T 1A receptor agonism. C om pound 4 4  has a 
p E R K 1 /2  versus 5-arrestin  bias factor o f 1 .43  (i.e., its E C 50 is 
alm ost 30-fold  low er for E R K 1 /2  phosphorylation than for fi- 
arrestin recru itm en t), while com pound 5 6  has a bias factor of  
—3.4 9 , translating to  over 3000-fo ld  greater p oten cy  for fi- 
arrestin recruitm ent than for p E R K 1 /2 . Interestingly, while 
b oth  com pounds displayed similar effectiveness in the Porsolt 
forced swim ming test (F S T ) for antidepressant activity, with 
4 4  being slightly m ore p oten t (m inim al effective dose M E D  = 
0 .1 6  m g /k g  p.o. for 4 4  vs 0 .6 3  m g /k g  p.o. for 5 6 ) ,  they differed 
significantly in their ability to  induce low er lip retraction  
(L L R ). L L R  is an autonom ic response, a com p onen t o f the rat 
“seroto n erg ic syn drom e”, attributed  to  5 -H T 1A recep to r  
activation .43 C om pound 4 4  did n ot induce any significant 
L LR , even up to  a dose 4 X  higher than the M E D  for 
antidepressant activity, while com pound 5 6  elicited a full L LR  
in a dose 2 X  low er than the M E D  in Porsolt test ( C h art 2 , 
Supporting Inform ation Tables S6  and S8 ) .
N otew orthily, at the tim e point that the in vivo effects were 
observed, we verified that there was a detectable exposure of  
the tested  com pounds in b oth  serum  and brain ( Supporting  
Inform ation C h art S1, Table S 1 0 ). M oreover, the above­
m entioned  pharm acological effects w ere reversed by the 
selective 5 -H T 1A rece p to r an tagonist W A Y 1 0 0 6 3 5 , thus 
testifying for their full 5 -H T 1A receptor dependence ( Support­
ing Inform ation Tables S7 and S 9 ).
T h e significance o f the L L R  effect for hum an condition is so 
far unknown. H ow ever, it is undoubtedly an autonom ic side 
effect, n ot connected  with the antidepressant-like response in 
rat, and has previously been considered to  be inseparable from  
the desired therapeutic-like effects resulting from  the 5 -H T 1A 
receptor activation .44 Interestingly, antidepressant-like activity  
in the F S T  is m ed iated  by activation  o f  the cortical 
p ostsy n ap tic su bp opu lation  o f  5 - H T 1A recep to rs , while 
induction o f L L R  is thought to  be m ediated by presynaptic 
5 -H T 1A autoreceptors localized in the Raphe nuclei.45,46 In the  
case o f 5 -H T 1A receptors, the contrasting roles o f  pre- and 
postsynaptic receptors in different brain regions have been  
extensively investigated, also in the con text o f  therapeutic  
effectiveness.16  T h e diverse pharm acological profiles o f  4 4  and 
5 6  are therefore o f considerable interest because they suggest 
that different preferences for 5 -arrestin recruitm ent relative to
E R K 1 /2  phosphorylation (functional selectivity at the cellular 
level) m ay be associated  w ith preferential activation o f  
particular subpopulations o f 5 -H T 1A receptors (brain region  
selectivity) and thus lead to  separate therapeutic and side 
effects. I t  should also be considered that such a high level o f fi- 
arrestin-biased agonism, reported for the first tim e in the 
present study, could open the way to novel opportunities for 
targetin g 5 -H T 1A recep to rs , w ith previously u nexplored  
physiological or behavioral outcom es. H ow ever, these are 
p relim inary  suggestions th a t n eed  to  be carefully and  
thoroughly evaluated using m ore num erous biased agonists 
and diversified technical approaches. Although these observa­
tions are prom ising and w arrant further investigation, formal 
d em onstration  o f  superior therapeutic activity by biased  
agonists ultim ately requires appropriately designed clinical 
trials and a clear understanding linking in vitro biased agonism  
to  disease m echanism s. N evertheless, the p resen t w ork  
provides com pelling evidence that chem ical m odifications of  
5 -H T 1A receptor-biased agonists allow for their functional 
diversification, which in turn translates to  distinct p harm aco­
logical effects in vivo.
■  C O N C L U SIO N S
T h e present w ork describes the SARs and SFA R s o f 5 -H T 1A 
receptor agonists and proves that novel and highly selective 
biased agonists can be designed to  exhibit distinct and  
innovative signaling profiles. Thus, a series o f 3 0  novel 
derivatives o f  1-(1-benzoylpiperidin-4-yl)m ethanam ine was 
synthesized and found to  exhibit high affinity for the 5 -H T 1A 
receptor (pK i > 8 .0 , L L E  > 5 .0 ) . Tw enty-seven o f  these had  
subnanom olar affinities (p K i > 9 .0 , L L E  > 6 ) and 15  
com pounds possessed higher lipophilic-ligand efficiencies 
than the lead com pound 3 . N otew orthily, com pound 5 6  was 
found to  be extrem ely potent, one o f the highest affinity 5- 
H T 1A receptor ligands discovered to  date (based on the 
C h E M B L  d atab ase). M o reo v er, m o st o f  the p resen ted  
com pounds showed substantial selectivity versus key anti- 
targets— the adrenergic a 1 and dopam inergic D 2 receptors (K i 
ratio over 1000-fo ld ). Twenty-five com pounds w ere selected  
and tested  in four functional assays con nected  with the 5 -H T 1A 
receptor activation, that is, E R K 1 /2  phosphorylation (p E R K 1 /
2 ) ,  adenylyl cyclase inhibition (cA M P ), calcium  mobilization  
(C a 2+), and fi-arrestin recruitm ent. Based on analysis o f  SFARs  
and o f bias factors, nine novel 5 -H T 1A receptor-biased agonists 
w ere identified that exhibit diversified functional activity
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profiles (i.e., “signaling fingerprints”) . T h e selected, m ost 
interesting biased agonists 4 4  and 5 6  displayed high selectivity  
versus a panel o f  4 5  off-target sites as well as prom ising  
m etabolic stability, high permeability, and low  hepatotoxicity, 
thus testifying for their favorable developability profiles. 
Strikingly, w hereas 4 4  exhibited m arked biased agonism  for 
activation o f  p E R K 1 /2 , 5 6  exhibited the opposite profile, with  
very poten t biased agonism  for ^-arrestin  recruitm ent. T h e  
profile o f 5 6  is, to  our knowledge, unprecedented and could  
constitute a novel class o f 5 -H T 1A receptor-biased agonists, an 
interpretation reinforced by the differential in vivo activity of  
the two com pounds in tests o f antidepressant-like activity  
(F S T )  and behavioral syndrom e (L L R ). 4 4  preferentially  
elicited antidepressant-like effects, w hereas 5 6  m ore potently  
elicited L L R , thus suggesting that the balance o f ^-arrestin  
recruitm ent relative to  E R K 1 /2  phosphorylation (functional 
selectivity) m ay be associated with accentuated  activity in 
specific physiological a n d /o r  behavioral m odels. As discussed  
previously, such differences likely reflect activation o f  particular 
subpopulations o f the 5 -H T 1A receptors (regional selectivity) 
and m ay accou nt for differential separation o f therapeutic and 
side effects .16,47,48 T h e novel 5 -H T 1A agonists described herein, 
displaying diversified functional profiles, m ay con stitu te  
prom ising tool drugs to  investigate the activity o f 5 -H T 1A 
receptor subpopulations and, potentially, could be developed  
as pharm acotherapeutics to  treat C N S disorders involving 
dysfunctional serotonergic neurotransm ission.
■  E X P E R IM E N T A L  SECTIO N
M olecular M odeling. Computer-aided ligand design and further 
studies on SARs were based on ligand—receptor interaction analysis. 
The previously built template of the 5-H T1B crystal structure (PDB  
ID 4IAR) 49 and preoptimized serotonin 5-H T 1A receptor homology 
model served as a structural target for docking studies.50 To capture 
distinctive binding mode of a variety of functionally biased ligands, 
the general procedure for developing ligand-optimized models using 
induced-fit technique51 served as both a ligand-steered binding site 
optimization method (in terms of amino acid side chains) and a 
routine docking approach, predicting bioactive conformation.13 Glide 
SP flexible docking procedure using an OPLS3 force field was set for 
the induced-fit docking (IFD ). H-bond constraint and centroid of a 
grid box for docking to the 5-H T 1A receptor were located on Asp3.32. 
Ligand structures were sketched in Maestro 2D  Sketcher and 
optimized using a LigPrep tool. The aforementioned tools were 
implemented in Small-Molecule Drug Discovery Suite (Schrodinger, 
Inc. New York, USA), which was licensed for Jagiellonian University 
Medical College. Instant JChem was used for structure database 
management and property prediction, Instant JChem  20.8.0, 2020, 
ChemAxon (http://www.chemaxon.com).
C hem istry. General Chemistry Information. All the reagents 
were purchased from commercial suppliers (Sigma-Aldrich, Merck, 
Chempur, Fluorochem, Enamine, Acros Organics, Manchester 
Organics, POCh, Activate Scientific, Chem-Impex International, 
Apollo Scientific) and were used without further purification. 
Analytical thin-layer chromatography was performed on Merck 
Kieselgel 6 0  F 254 (0 .25  mm) precoated aluminum sheets (Merck, 
Darmstadt, Germany). Compounds were visualized with UV light and 
by suitable visualization reagents 2 .9 % solution of ninhydrin in a 
mixture of 1-propanol and acetic acid (1 0 0 /3 , v /v ) and Pancaldi 
reagent [solution of 12.0 g (N H 4) 6Mo7O24, 0.5 g Ce(SO 4^  and 6.8 
mL of 98% H 2SO4 in 240 mL of water]. Flash chromatography was 
performed on CombiFlash R F (Teledyne Isco) using disposable silica 
gel flash columns RediSep Rf (silica gel 60, particle size 4 0 —63 ^m) 
and RediSep Gold (silica gel 60, particle size 20—40 ^m ) purchased 
from Teledyne Isco. The ultraperformance liquid chromatography 
(U P L C )—mass spectrometry (M S) or U PLC —tandem mass spec­
trometry (M S/M S) analysis was done on a U PLC—M S/M S system 
comprising a Waters A CQ U ITY U PLC (W aters Corporation, 
Milford, MA, USA) coupled with a Waters tandem quadrupole 
(TQ D ) mass spectrometer (electrospray ionization (ESI) mode with 
TQ D ). Chromatographic separations were carried out using the 
ACQ UITY UPLC BEH  (bridged ethyl hybrid) C18 column: 2.1 X  
100 mm and 1.7 ^m particle size. The column was maintained at 40  
°C and eluted under gradient conditions using 95—0% of eluent A  
over 10 min at a flow rate of 0.3 mL/min. Eluent A: 0.1% solution of 
formic acid in water (v /v ); eluent B: 0 .1 % solution of formic acid in 
acetonitrile (v /v ). A total of 10 of each sample was injected and 
chromatograms were recorded using a Waters eX photodiode array 
detector. The spectra were analyzed in the range of 2 0 0 —700 nm with
1.2 nm resolution and at a sampling rate of 20 points/s. The U PLC — 
MS purity of all the test compounds and key intermediates were 
determined to be >95%. 1H NMR, 13C NMR, and 19F NMR spectra 
were obtained in a Varian Mercury spectrometer (Varian Inc., Palo 
Alto, CA, USA) and JEO L spectrometer (JEO L SAS., Tokyo, Japan), 
in C D O 3, CD3OD, or DMSO-^6 operating at 300 MHz ( 1H NM R), 
75 MHz or 126 MHz ( 13C NM R), and 282 MHz ( 19F N M r). 
Chemical shifts are reported as 8 values (ppm) relative to TMS 8  = 0 
( 1H ) as internal standard (IS). The J  values are expressed in Hertz 
(H z). Signal multiplicities are represented by the following 
abbreviations: s (singlet), br s (broad singlet), bd (broad doublet), 
d (doublet), dd (doublet of doublets), dt (doublet of triplets), t 
(triplet), td (triplet of doublets), tdd (triplet of doublet of doublets), 
q (quartet), dq (doublet of quartets), and m (multiplet). Melting 
points were determined on a Buchi Melting Point B-540 apparatus 
using open glass capillaries and are uncorrected.
Synthetic P rocedures. Previously reported or commercially 
available compounds:
2-(1-(3-Chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydrox- 
yacetonitrile ( 4 ) ,13
2-(1-(3,4-Dichlorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyace-
tonitrile (5 ) ,13
2-(2-Chlorophenoxy)ethanamine (9 ).
D etailed  P ro ced u res for th e  P rep aratio n  o f th e  A m ine  
In te rm e d ia te s  6 —2 6  A re D escrib ed  in th e  S u p p o rtin g  
Inform ation. General Procedures for the Preparation o f  1-(1- 
Benzoylpiperidin-4-yl)methanamine Derivatives (2 7 —57). To ap­
propriate cyanohydrin (4  or 5 ) 13 (1 .0  equiv) dissolved in methanol, 
DABCO (2 .0—12.5 equiv) was added in one portion, followed by the 
appropriate amine (6 —2 6 ) (1 .0—1.6 equiv), 4  c5 molecular sieves, 
sodium cyanoborohydride (1 .6 —7.8 equiv), and iron sulfate 
heptahydrate (FeSO 4 X 7 H 2O) (1.1 equiv). The mixture was stirred 
at room temperature until the cyanohydrin was consumed (2 4 —72 h ); 
then, the reaction mixture was filtered, concentrated in vacuo, and 
next brine was added. The resulting mixture was extracted with 
EtOAc (3 X ), organics were combined and dried over magnesium 
sulfate, filtered, and concentrated. The crude product was purified by 
flash chromatography.
tert-Butyl (3-(2-'(((1-(3-Chloro-4-fluorobenzoyl)-4-fluoropiperi- 
din-4-yl)m ethyl)am ino)ethoxy)phenyl)(m ethyl)carbam ate (27). 
The title compound was prepared using 2-(1-(3-chloro-4-fluoroben- 
zoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (4 )  (0 .110 g, 0.35 
mmol) tert-butyl (3-(2-aminoethoxy)phenyl)(methyl)carbamate (1 7 )  
(0 .12 0  g, 0.45 mmol), DABCO (0 .487 g, 4 .34  mmol), sodium 
cyanoborohydride (0 .167 g, 2.71 mmol), molecular sieves (0 .900 g), 
and iron sulfate heptahydrate (0.106 g, 0.38 mmol) in methanol (5 
m L). Purification: DCM /m ethanol/N H 3(aq) (9 .5 /0 .5 /0 .0 2 , v /v /v ). 
Yield: 40%; colorless oil. 1H NM R (300  MHz, CDCl3, 8 ): 7.48 (dd, J  
= 1.8, 7.0 Hz, 1H), 7 .33—7.25 (m, 1H), 7.19 (td, J  = 8.3, 11.6 Hz, 
2H ), 6 .86—6.77 (m, 2H ), 6 .74—6.65 (m, 1H), 4.51 (br s, 1H), 4.04  
(t, J  = 5.3 Hz, 2H ), 3.58 (br s, 1H), 3.35 (br s, 1H), 3.23 (s, 3H ), 
3.20—3.08 (m, 1H), 3.02 (t, J  = 5.0 Hz, 2H ), 2 .91—2.75 (m, 2 h ) ,  
2.00  (br s, 2H ), 1.64 (br s, 3H ), 1.45 (s, 9H ). Formula: 
C27H 34ClF2N 3O4; MS (ESI+) m /z: 538 [M + H+].
(3-C hloro-4-fluorophenyl)(4-fluoro-4-(((2-(2-fluorophenoxy)-  
ethyl)am ino)m ethyl)piperidin-1-yl)m ethanone (28). The title com­
pound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoro-
10961 https://dx.doi.org/10.1021/acs.jmedchem.0c00814
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piperidin-4-yl)-2-hydroxyacetonitrile (4 )  (0 .150 g, 0.48 mmol), 2-(2- 
fluorophenoxy)ethanamine ( 6 ) (0 .118 g, 0.76 mmol), DABCO  
(0 .669 g, 5.97 mmol), sodium cyanoborohydride (0 .234  g, 3.73 
mmol), molecular sieves (1.043 g), and iron sulfate heptahydrate 
(0 .146 g, 0.53 mmol) in methanol (5 m L). Purification: EtO A c/ 
methanol (9 .5 /0 .5 , v /v ). Yield: 72%; pale yellow crystallizing oil. 1H 
N M R (300  MHz, CDCl3, S): 7 .5 1 -7 .4 5  (m, 1H), 7 .3 3 -7 .2 5  (m, 
1H), 7 .2 1 -7 .1 3  (m, 1H ), 7 .1 1 -7 .0 1  (m, 2 h ) ,  7 .0 1 -6 .8 6  (m, 2H ), 
4.50 (br s, 1H), 4.13 (t, J  = 5.0 Hz, 2H ), 3.58 (br s, 1H), 3 .4 7 -3 .1 4  
(m, 2H ), 3.05 (t, J  = 5.0 Hz, 2H ), 2.86 (d, J  = 19.9 Hz, 2H ), 2.00 (s, 
2H ), 1 .8 3 -1 .5 1  (m, 3H ). 13C NM R (75 MHz, CDCl3, s ) :  168.0,
158.8 (d, J  = 254  Hz), 152.8 (d, J  = 246.4 Hz), 146.8 (d, J =  10.4 Hz),
132.9 (d, J  = 4 .6 Hz), 129.7, 127.1 (d, J  = 6.9 Hz), 124.3 (d, J  = 3.5 
H z), 121.5 (d, J  = 18.4 Hz), 121.5 (d, J  = 6.9 Hz), 116.8 (d, J  = 22  
H z), 116.3 (d, J  = 18.4 Hz), 115.3, 94.4 (d, J  = 172 Hz), 69.2, 57.2 (d, 
J  = 22 Hz), 49.2, 43.6, 38.2, 33.4, 32.6. Formula: C 21H22ClF3N 2O2; 
MS (ESI+) m /z: 427  [M + H+].
(3-C hloro-4-fluorophenyl)(4-fluoro-4-(((2-(3-fluorophenoxy)- 
ethyl)am ino)m ethyl)piperidin-1-yl)m ethanone (29). The title com­
pound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoro- 
piperidin-4-yl)-2-hydroxyacetonitrile (4 )  (0 .150 g, 0.48 mmol), 2-(3- 
fluorophenoxy)ethanamine (7 )  (0 .118 g, 0.76 mmol), DABCO  
(0 .669 g, 5.97 mmol), sodium cyanoborohydride (0 .234  g, 3.73 
mmol), molecular sieves (1.043 g), and iron sulfate heptahydrate 
(0 .146 g, 0.53 mmol) in methanol (5 m L). Purification: n-hexane/ 
EtO Ac/m ethanol/N H 3(aq) (5 /4 .5 /0 .5 /0 .0 2 , v /v /v /v ). Yield: 40%; 
white crystallizing oil. 1]-I NM R (300  MHz, C D O 3, S): 7.48 (dd, J  =
2.1, 6.9 Hz, 1H), 7 .3 3 -7 .2 6  (m, 1H), 7 .2 4 -7 .1 3  (m, 2H ), 6.67 (tdd, J  
= 1 .0, 2 .0, 9.5 Hz, 2 H ), 6 .6 4 -6 .5 8  (m, 1 H ), 4.51 (br s, 1H ), 4 .04  (t, J  
= 5.0 Hz, 2H ), 3.60 (br s, 1H ), 3 .4 6 -3 .1 0  (m, 2H ), 3.03 (t, J  = 5.1 
Hz, 2H ), 2 .9 0 -2 .7 7  (m, 2H ), 2.01 (br s, 2H ), 1.63 (br s, 3H ). 13C 
N M R (75 MHz, CDCl3, S): 168.1, 163.6 (d, J  = 245 Hz), 160.1 (d, J  
= 11.1 H z), 158.8 (d, J  = 254 Hz), 132.9 (d, J  = 4 .4  Hz), 130.2 (d, J  = 
10 H z), 129.7, 127.1 (d, J  = 7.7 Hz), 121.5 (d, J  = 18.2 H z), 116.8 (d, 
J  = 22 Hz), 110.2 (d, J  = 2.8 Hz), 107.7 (d, J  = 22 H z), 102.2 (d, J  = 
24  Hz), 94 .4  (d, J  = 172 Hz), 67.7, 57.3 (d, J  = 22 Hz), 49.1, 43.9,
38.6, 33.5, 32.8. Formula: C 21H 22ClF3N 2O2; MS (ESI+) m /z: 427  [M  
+ H+].
(3 ,4-D ichlorophenyl)(4-fluoro-4-(((2-(3-fluorophenoxy)ethyl)-  
am ino)m ethyl)piperidin-1-yl)methanone (30). The title compound 
was prepared using 2-(1-(3,4-dichlorobenzoyl)-4-fluoropiperidin-4- 
yl)-2-hydroxyacetonitrile ( 5 )  (0 .1 5 0  g, 0 .4 5  m m ol), 2 -(3 -  
fluorophenoxy)ethanamine (7 )  (0 .064  g, 0.41 mmol), DABCO  
(0 .634 g, 5.66 mmol), sodium cyanoborohydride (0 .034  g, 0.54  
mmol), molecular sieves (0.500 g), and iron sulfate heptahydrate 
(0 .137 g, 0.50 mmol) in methanol (8  m L). Purification: n-hexane/ 
E t2O /D C M /m eth an o l/N H 3(aq) ( 2 /2 /5 .5 /0 .5 /0 .0 2 ,  v /v /v /v /v ) .  
Yield: 35%; yellow transparent oil. 1H NM R (300  MHz, C D O 3, S): 
7 .5 7 -7 .4 2  (m, 2H ), 7 .2 6 -7 .1 7  (m, 2H ), 6 .7 3 -6 .5 5  (m, 3H ), 4 .52  (br 
s, 1H), 4 .04  (t, J  = 5.1 Hz, 2H ), 3.59 (br s, 1H), 3 .4 4 -3 .1 0  (m, 2H ),
3.03 (t, J  = 5.0 Hz, 2H ), 2 .9 1 -2 .7 5  (m, 2H ), 2.01 (br s, 2H ), 1.62 (br 
s, 3H ). 13C NM R (75 MHz, CDCl3, S): 167.9, 163.6 (d, J  = 245.4  
H z), 160.1 (d, J  = 10.4 Hz), 135.6, 134.1, 133.0, 130.6, 130.2 (d, J  = 
10.4 Hz), 129.1, 126.2, 110.2 (d, J  = 2.3 Hz), 107.7 (d, J  = 20 Hz),
102.2 (d, J  = 24  Hz), 94.3 (d, J  = 172 Hz), 67.6, 57.3 (d, J  = 22 Hz),
49.1, 43.5, 38.2, 33.4, 32.6. Formula: C 21H 22Cl2F 2N 2O2; MS (ESI+) 
m /z: 443 [M + H+].
(3-C h lo m -4-flu o m ph en y l)(4-flu om -4-(((2-(4-flu oro p heno xy )-  
ethyl)am ino)m ethyl)piperidin-1-yl)m ethanone (31). The title com­
pound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoro- 
piperidin-4-yl)-2-hydroxyacetonitrile (4 )  (0 .100 g, 0.32 mmol), 2-(4- 
fluorophenoxy)ethanamine ( 8 ) (0 .074  g, 0.48 mmol), DABCO  
(0 .444 g, 3.97 mmol), sodium cyanoborohydride (0.155 g, 2.48 
mmol), molecular sieves (0.900 g), and iron sulfate heptahydrate 
(0 .097 g, 0.35 mmol) in methanol (4  m L). Purification: n-hexane/ 
EtO Ac/m ethanol/N H 3(aq) (6 /3 .5 /0 .5 /0 .0 2 , v /v /v /v ). Yield: 64%; 
white crystallizing oil. 11̂  NM R (300  MHz, C D O 3, S): 7.48 (dd, J  = 
2.3, 7.0 Hz, 1H), 7 .3 3 -7 .2 4  (m, 1H), 7 .2 2 -7 .1 1  (m, 1H), 7 .0 1 -6 .9 0  
(m, 2H ), 6 .8 8 -6 .7 8  (m, 2H ), 4.51 (br s, 1H), 4 .02  (t, J  = 5.3 Hz, 
2H ), 3.62 (d, J  = 19.3 Hz, 1H), 3 .4 8 -3 .1 0  (m, 2H ), 3.01 (t, J  = 5.0
Hz, 2H ), 2.83 (d, J  = 19.9 Hz, 2H ), 2 .0 6 -1 .9 4  (m, 2H ), 1 .8 3 -1 .4 5  
(m, 3H ). 13C NM R (75 MHz, CDCl3, S): 168.1, 158.8 (d, J  = 253  
H z), 157.3 (d, J  = 238 Hz), 154.9, 132.9 (d, J  = 4.6 Hz), 129.7, 127.1 
(d, J  = 6.9 Hz), 121.5 (d, J  = 18.4 Hz), 116.8 (d, J  = 2 2  Hz), 115.8 (d, 
J  = 23 Hz, 2C ), 115.5 (d, J  = 8.1 Hz, 2C ), 94.3 (d, J  = 172 Hz), 68.0,
57.3 (d, J  = 22 H z), 49.3, 43.7, 38.3, 33.6, 32.7. Formula: 
C21H 22ClF3N 2O2; MS (ESI+) m /z: 427  [M + H+].
(3-C hloro-4-fluorophenyl)(4-fluoro-4-(((2-(2-chlorophenoxy)- 
ethyl)am ino)m ethyl)piperidin-1-yl)m ethanone (32). The title com­
pound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoro- 
piperidin-4-yl)-2-hydroxyacetonitrile (4 )  (0 .150 g, 0.48 mmol), 2-(2- 
chlorophenoxy)ethanamine (9 )  (0.131 g, 0 .76 mmol), DABCO 
(0 .669 g, 5.97 mmol), sodium cyanoborohydride (0 .234  g, 3.73 
mmol), molecular sieves (1.043 g), and iron sulfate heptahydrate 
(0 .146 g, 0.53 mmol) in methanol (5 m L). Purification: D C M / 
methanol (9 .5 /0 .5 /0 .0 2 , v /v /v ) and then n-hexane/EtOAc/meth- 
anol/N H 3(aq) (6 /3 .5 /0 .5 /0 .0 2 , v /v /v /v ). Yield: 48%; beige crystalliz­
ing oil. ^  NM R (300  MHz, CDCl3, S): 7 .47 (dd, J  = 1.8, 7.0 Hz, 
1H), 7.35 (dd, J  = 1.8, 7.6 Hz, 1H), 7 .3 2 -7 .2 6  (m, 1H), 7 .2 4 -7 .1 2  
(m, 2H ), 6 .9 6 -6 .8 4  (m, 2H ), 4 .49  (br s, 1H), 4 .12  (t, J  = 5.0 Hz, 
2H ), 3.59 (d, J  = 5.9 Hz, 1H), 3 .4 5 -3 .1 2  (m, 2H ), 3.07 (t, J  = 5.0 Hz, 
2 h ) ,  2 .9 5 -2 .8 0  (m, 2H ), 2.00 (br s, 2H ), 1.84 (s, 1H), 1 .7 7 -1 .5 3  
(m, 2H ). 13C NM R (75 MHz, CDCl3, S): 168.0, 158.8 (d, J  = 254  
H z), 154.2, 132.9 (d, J  = 4 .6 H z), 130.3, 129.7, 127.8, 127.1 (d, J  =
6.9 Hz), 123.0, 121.7, 121.5 (d, J  = 18.4 Hz), 116.8 (d, J  = 2 2  Hz),
113.7, 94.4 (d, J  = 1 7 2  Hz), 68.9, 57.2 (d, J  = 22 H z), 49.0, 43.7, 38.2,
33.5, 32.7. Formula: C 21H 22Cl2F 2N 2O2; MS (ESI+) m /z: 443 [M + 
H+].
(3 -C h lo ro -4 -flu o ro p h en y l)(4 -(((2 -(3 -ch lo ro p h en o x y )eth y l)-  
amino)m ethyl)-4-fluoropiperidin-1-yl)m ethanone (33). The title 
compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4- 
fluoropiperidin-4-yl)-2-hydroxyacetonitrile (4 )  (0 .150 g, 0.48 mmol), 
2-(3-chlorophenoxy)ethanamine (1 0 )  (0.131 g, 0 .76 mmol), DABCO 
(0 .669 g, 5.97 mmol), sodium cyanoborohydride (0 .234  g, 3.73 
mmol), molecular sieves (1.043 g), and iron sulfate heptahydrate 
(0 .146 g, 0.53 mmol) in methanol (5  m L). Purification: n-hexane/ 
EtO Ac/m ethanol/N H 3(aq) (5 /4 .5 /0 .5 /0 .0 2 , v /v /v /v ). Yield: 28%; 
beige crystallizing oil. ^  NM R (300  MHz, C D O 3, S): 7.48 (dd, J  =
2.1, 6.9 Hz, 1H), 7 .3 3 -7 .2 6  (m, 1H), 7.18 (dt, J  = 5.1, 8.3 Hz, 2H ), 
6 .9 6 -6 .9 1  (m, 1 H ), 6.90 (t, J  = 2 .1  Hz, 1 h ) ,  6.78 (ddd, J  = 0 .8, 2.4,
8.3 Hz, 1H), 4 .52 (br s, 1H), 4 .04  (t, J  = 5.0 Hz, 2h ), 3.60 (br s, 1H), 
3.37 (br s, 2H ), 3.02 (t, J  = 5.1 Hz, 2H ), 2 .9 0 -2 .7 7  (m, 2H ), 2.02 (br 
s, 2H ), 1.63 (s, 3H ). 13C NM R (75 MHz, CDCl3, S): 168.1, 159.5,
158.8 (d, J  = 254 H z), 134.9, 132.9 (d, J  = 4 .4 Hz), 130.2, 129.7,
127.1 (d, J  = 7.7 Hz), 121.7, 121.1, 116.8 (d, J  = 22 Hz), 114.9, 113.0,
94.3 (d, J  = 172 Hz), 67.6, 57.3 (d, J  = 22 Hz), 49.1, 43.3, 39.6, 33.3 
(2C ). Formula: C21H 22Cl2F 2N 2O2; MS (ESI+) m /z: 443 [m  + H+].
(4-(((2-(3-Chlorophenoxy)ethyl)am ino)m ethyl)-4-fluoropiperi- 
din-1-yl)(3,4-dichlorophenyl)methanone (34). The title compound 
was prepared using 2-(1-(3,4-dichlorobenzoyl)-4-fluoropiperidin-4- 
yl)-2-hydroxyacetonitrile ( 4 )  (0 .1 5 0  g, 0 .4 5  m m ol), 2 -(3 -  
chlorophenoxy)ethanamine (1 0 )  (0 .070 g, 0.41 mmol), DABCO 
(0 .634 g, 5.66 mmol), sodium cyanoborohydride (0 .034  g, 0.54  
mmol), molecular sieves (0.500 g), and iron sulfate heptahydrate 
(0 .137 g, 0.50 mmol) in methanol (8  m L). Purification: n-hexane/ 
EtO Ac/m ethanol/N H 3(aq) (4 /5 .5 /0 .5 /0 .0 2 , v /v /v /v ). Yield: 36%; 
yellow oil. 1H NM R (300  MHz, CDCl3, S): 7 .5 3 -7 .4 6  (m, 2H ), 
7 .2 5 -7 .1 5  (m, 2H ), 6 .9 7 -6 .8 7  (m, 2H ), 6.78 (ddd, J  = 1.0, 2.4, 8.3 
Hz, 1H), 4.52 (br s, 1H), 4 .04  (t, J  = 5.1 Hz, 2H ), 3.59 (br s, 1H), 
3 .4 6 -3 .1 2  (m, 2H ), 3.02 (t, J  = 5.1 Hz, 2H ), 2 .9 1 -2 .7 6  (m, 2 h ) ,
2.00 (d, J  = 12.3 Hz, 2h ), 1.61 (br s, 3H ). 13C NM R (75 MHz, 
CDCl3, S): 167.9, 159.5, 135.6, 134.9, 134.1, 133.0, 130.6, 130.2,
129.1, 126.2, 121.1, 114.9, 113.0, 94.3 (d, J  = 172 Hz), 67.6, 57.2 (d, J  
= 22 H z), 49.1, 43.5, 38.2, 33.5, 32.9. Formula: C21H 22Cl3FN 2O2; MS 
(ESI+) m /z: 459  [M  + H+].
(3-C hloro-4-fluorophenyl)(4-fluoro-4-(((2-(4-chlorophenoxy)- 
ethyl)am ino)m ethyl)piperidin-1-yl)m ethanone (35). The title com­
pound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoro- 
piperidin-4-yl)-2-hydroxyacetonitrile (4 )  (0 .100 g, 0.32 mmol), 2-(4- 
chlorophenoxy)ethanamine (1 1 )  (0 .082 g, 0.48 mmol), DABCO
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(0 .444 g, 3.97 mmol), sodium cyanoborohydride (0.155 g, 2.48 
mmol), molecular sieves (0.900 g), and iron sulfate heptahydrate 
(0 .097 g, 0.35 mmol) in methanol (4  m L). Purification n-hexane/ 
EtO Ac/m ethanol/N H 3(aq) (6 /3 .5 /0 .5 /0 .0 2 , v /v /v /v ). Yield: 64%; 
white oil. 1H NM R (300  MHz, CDCl3, S): 7.48 (dd, J  = 2.1, 6.7 Hz, 
1H), 7 .34—7.12 (m, 4H ), 6 .87—6.77 (m, 2H ), 4 .50  (br s, 1H), 4.02  
(t, J  = 5.0 Hz, 2H ), 3 .74—3.49 (m, 1H), 3.24 (br s, 2H ), 3.02 (t, J  =
5.0 Hz, 2H ), 2 .91—2.74 (m, 2H ), 2.00 (br s, 2H ), 1.88—1.44 (m, 3H ). 
13C N M R (75 MHz, CDCl3, S): 168.1, 157.4, 158.8 (d, J  = 254  Hz),
132.9 (d, J  = 4.6 Hz), 129.7, 129.3 (2C ), 127.1 (d, J  = 6.9 Hz), 125.8,
121.5 (d, J  = 18.4 Hz), 116.8 (d, J  = 2 2  Hz), 115.7 (2 C ), 94.3 (d, J  = 
172 Hz), 67.7, 57.3 (d, J  = 22 Hz), 49.2, 43.7, 38.3, 33.6, 32.8. 
Formula: C 21H 22Cl2F 2N 2O2; MS (ESI+) m /z: 443 [M  + H+].
(3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-(2-m ethoxyphenoxy)- 
ethyl)am ino)m ethyl)piperidin-1-yl)m ethanone (36). The title com­
pound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoro- 
piperidin-4-yl)-2-hydroxyacetonitrile (4 )  (0.505 g, 1.61 mmol), 2-(2- 
methoxyphenoxy)ethanamine (1 2 ) (0 .430 g, 2.58 mmol), DABCO 
(2 .256 g, 20.11 mmol), sodium cyanoborohydride (0.788 g, 12.55 
mmol), and molecular sieves (3.300 g) in methanol (15  mL). 
Purification: n-hexane/EtOAc/methanol/NH 3(aq) (6 /3 .5 /0 .5 /0 .0 2 , v / 
v /v /v ). Yield: 35%; pale yellow crystallizing oil. H N M R (300  MHz, 
CDCl3, S): 7.48 (dd, J  = 2.1, 6.9 Hz, 1H), 7 .32—7.26 (m, 1H), 7 .20— 
7.13 (m, 1H), 6 .98—6.85 (m, 4H ), 4 .50  (br s, 1H), 4 .12  (t, J  = 5.3 Hz, 
2H ), 3.84 (s, 3H ), 3 .60 (br s, 1H), 3 .45—3.13 (m, 2H ), 3 .04  (t, J  =
5.3 Hz, 2 h ) ,  2 .91—2.79 (m, 2H ), 2 .10—1.92 (m, 2H ), 1.70 (br s, 3H ). 
19F NM R (282  MHz, CDCl3, s ) : —112.7 (s, 1F), —166.3 (s, 1F). 13C 
N M R (75 MHz, CDCl3, S): 168.0, 158.8 (d, J  = 245 Hz), 149.8,
148.2, 132.9 (d, J  = 4.4- Hz), 129.7, 127.1 (d, J  = 7.7 Hz), 121.6,
121.4, 120.9, 116.8 (d, J  = 22 Hz), 114.2, 111.9, 94.4 (d, J  = 172 Hz),
69.0, 57.3 (d, J  = 22 Hz), 55.8, 49.3, 43.8, 38.3, 33.6, 32.8. Formula: 
C22H 25ClF2N 2O3; MS (ESI+) m /z: 439  [M + H+].
(3,4-Dichlom phenyl)(4-fluom -4-(((2-(2-m ethoxyphenoxy)ethyl)- 
am ino)m ethyl)piperidin-1-yl)methanone (37). The title compound 
was prepared using 2-(1-(3,4-dichlorobenzoyl)-4-fluoropiperidin-4- 
yl)-2-hydroxyacetonitrile ( 5 )  (0 .3 5 0  g, 1 .06  m m ol), 2 -(2 -  
methoxyphenoxy)ethanamine (1 2 ) (0 .282 g, 1.69 mmol), DABCO 
(1 .479 g, 13.18 mmol), sodium cyanoborohydride (0.518 g, 8.25 
mmol), and molecular sieves (2 .194 g) in methanol ( 1 0  mL). 
Purification: n-hexane/EtOAc/methanol/NH 3(aq) (6 /3 .5 /0 .5 /0 .0 2 , v / 
v /v /v ). Yield: 30%; pale yellow crystallizing oil. H N M R (300  MHz, 
CDCl3, S): 7 .53—7.45 (m, 2H ), 7.23 (dd, J  = 1.8, 8.2 Hz, 1H), 6 .99— 
6.84 (m, 4H ), 4.51 (br s, 1H), 4.12 (t, J  = 5.3 Hz, 2H ), 3 .84  (s, 3H ), 
3.57 (br s, 1H), 3 .46—3.10 (m, 2H ), 3 .04 (t, J  = 5.1 Hz, 2H ), 2.91 —
2.78 (m, 2H ), 2.00 (br s, 2H ), 1.77 (br s, 3H ). 13C NM R (75 MHz, 
CDCl3, S): 167.9, 149.7, 148.2, 135.7, 134.1, 133.0, 130.6, 129.1,
126.2, 121.6, 120.9, 114.2, 111.9, 94.3 (d, J  = 172 Hz), 69.0, 57.3 (d, J  
= 22  H z ), 5 5 .8 , 4 9 .3 , 4 3 .6 , 3 8 .2 , 3 3 .4 , 3 2 .7 . Form ula: 
C22H 25Cl2FN 2O3; MS (ESI+) m /z: 455 [M + H+].
(3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-(3-m ethoxyphenoxy)- 
ethyl)am ino)m ethyl)piperidin-1-yl)m ethanone (38). The title com­
pound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoro- 
piperidin-4-yl)-2-hydroxyacetonitrile (4 )  (0.165 g, 0.52 mmol), 2-(3- 
methoxyphenoxy)ethanamine (1 3 ) (0 .140 g, 0.84 mmol), DABCO 
(0 .734 g, 6.55 mmol), sodium cyanoborohydride (0 .256 g, 4.09  
mmol), molecular sieves (1.043 g), and iron sulfate heptahydrate 
(0.165 g, 0.58 mmol) in methanol (5 m L). Purification: n-hexane/ 
EtO Ac/m ethanol/N H 3(aq) (8 /1 .5 /0 .5 /0 .0 2 , v /v /v /v ). Yield: 40%; 
yellow transparent oil. 1]^ NM R (300  MHz, C D O 3, S): 7.48 (dd, J  =
2.1, 6.9 Hz, 1H), 7 .33—7.26 (m, 1H), 7 .21—7.13 (m, 2H ), 6 .54—6.48 
(m, 2H ), 6 .47—6.45 (m, 1H), 4 .52  (br s, 1H), 4.05 (t, J  = 5.1 Hz, 
2H ), 3.78 (s, 3H ), 3 .59 (br s, 1H), 3 .45—3.11 (m, 2H ), 3.02 (t, J  =
5.0 Hz, 2 h ) ,  2 .91—2.76 (m, 2H ), 2.01 (br s, 2H ), 1.71 (br s, 3H ). 13C 
N M R (75 MHz, CDCl3, S): 168.1, 160.8, 160.0, 158.8 (d, J  = 254  
H z), 132.9 (d, J  = 4 .4  H z), 129.9, 129.7, 127.1 (d, J  = 7.7 H z), 121.5 
(d, J  = 18.2 H z), 116.8 (d, J  = 22 Hz), 106.7, 106.4, 101 .0 ,94 .3  (d, J  = 
172 H z), 67.3, 57.3 (d, J  = 22 Hz), 55.3, 49.3, 43.6, 38.2, 33.6, 32.8. 
Formula: C 22H 25ClF2N 2O3; MS (ESI+) m /z: 439 [M  + H+].
(3,4-Dichlorophenyl)(4-fluoro-4-(((2-(3-m ethoxyphenoxy)ethyl)- 
am ino)m ethyl)piperidin-1-yl)methanone (39). The title compound
was prepared using 2-(1-(3,4-dichlorobenzoyl)-4-fluoropiperidin-4- 
yl)-2-hydroxyacetonitrile ( 5 )  (0 .1 2 4  g, 0 .3 7  m m ol), 2 -(3 -  
methoxyphenoxy)ethanamine (1 3 ) (0 .100 g, 0.60 mmol), DABCO 
(0 .524 g, 4.68 mmol), sodium cyanoborohydride (0.183 g, 2.91 
mmol), and molecular sieves (0.776 g) in methanol (4  mL). 
Purification: n-hexane/EtOAc/m ethanol/NH 3(aq) (8 /1 .5 /0 .5 /0 .0 2 ,  
v /v /v /v ). Yield: 30%; yellow oil. 1H NM R (300  MHz, CDCl3, S):
7 .53—7.47 (m, 2H ), 7.23 (dd, J  = 1.8, 8.2 Hz, 1H), 7.18 (t, J  = 8.1 Hz, 
1H), 6 .56—6.43 (m, 3H ), 4.51 (br s, 1H), 4.05 (t, J  = 5.1 Hz, 2H ), 
3.79 (s, 3H ), 3.60 (br s, 1H), 3.38 (br s, 2H ), 3.02 (t, J  = 5.0 Hz, 2 h ) ,  
2.90—2.78 (m, 2 h ) ,  2.01 (br s, 2H ), 1.59 (br s, 3H ). 13C NM R (126  
MHz, CDCl3, S): 168.0, 160.9, 160.1, 135.7, 134.2, 133.1, 130.7,
130.0, 129.2, 126.3, 106.8, 106.5, 101.1, 94.4 (d, J  = 172.6 H z), 67.4,
57.4 (d, J  = 21.7 H z), 55.4, 49 .4 ,43 .7 , 38.2, 33.7 (d, J  = 22.9 Hz), 32.8 
(d, J  = 21.1 H z). Formula: C22H 25Cl2FN 2O3; MS (ESI+) m /z: 455 [M  
+ H+].
(3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-(4-m ethoxyphenoxy)- 
ethyl)am ino)m ethyl)piperidin-1-yl)m ethanone (40). The title com­
pound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoro- 
piperidin-4-yl)-2-hydroxyacetonitrile (4 )  (0 .150 g, 0.48 mmol), 2-(4- 
methoxyphenoxy)ethanamine (1 4 ) (0 .128 g, 0.77 mmol), DABCO 
(0 .669 g, 5.97 mmol), sodium cyanoborohydride (0 .234  g, 3.73 
mmol), molecular sieves (1.043 g), and iron sulfate heptahydrate 
(0 .146 g, 0.53 mmol) in methanol (5  m L). Purification: n-hexane/ 
EtO A c/m ethanol/N H 3(aq) (6 /3 .5 /0 .5 /0 .0 2 , v /v /v /v )  and then 
EtOAc/methanol (9 /1 , v /v ). Yield: 51%; colorless oil. 1H NM R  
(300  MHz, CDCl3, S): 7.48 (dd, J  = 2.1, 6.9 Hz, 1H), 7 .33—7.26 (m, 
1H), 7 .22—7.14 (m, 1H), 6.83 (s, 4H ), 4 .50  (br s, 1H), 4.01 (t, J  =
5.1 Hz, 2H ), 3.76 (s, 3 h ) ,  3.60 (br s, 1H), 3 .44—3.13 (m, 2H ), 3.00  
(t, J  = 5 .1  Hz, 2H ), 2 .90—2.78 (m, 2H ), 2.02 (s, 2H ), 1.64 (br s, 3H ). 
13C N M R (75 MHz, CDCl3, S): 168.1, 158.8 (d, J  = 254  Hz), 154.0, 
152.9, 132.9 (d, J  = 4 .4 Hz), 129.7, 127.1 (d, J  = 7.7 Hz), 121.5 (d, J  =
18.2 Hz), 116.8 (d, J  = 22 Hz), 115.5 (2 C ), 114.7 ( 2 c ) ,  94.3 (d, J  = 
172 H z), 68.0, 57.3 (d, J  = 22 Hz), 55.7, 49.4, 43.8, 38.2, 33.8, 33.1. 
Formula: C22H 25ClF2N 2O3; MS (ESI+) m /z: 439  [M + H+].
(3,4-Dichlorophenyl)(4-fluoro-4-(((2-(4-m ethoxyphenoxy)ethyl)- 
am ino)m ethyl)piperidin-1-yl)methanone (41). The title compound 
was prepared using 2-(1-(3,4-dichlorobenzoyl)-4-fluoropiperidin-4- 
yl)-2-hydroxyacetonitrile ( 5 )  (0 .3 5 0  g, 1 .06  m m ol), 2 -(4 -  
methoxyphenoxy)ethanamine, (1 4 ) (0 .265 g, 1.59 mmol), DABCO 
(1 .479 g, 13.18 mmol), sodium cyanoborohydride (0.518 g, 8.25 
mmol), and molecular sieves (2 .194 g) in methanol (10  mL). 
Purification: EtOAc/methanol (9 .9 /0 .1 , v /v). Yield: 30%; pale yellow 
crystallizing oil. 1H NM R (300 MHz, CDCl3, S): 7 .54—7.44 (m, 2H ), 
7.23 (dd, J  = 2.1, 8.2 Hz, 1H), 6.83 (s, 4H ), 4.52 (br s, 1H ), 4.01 (t, J  
= 5.1 Hz, 2H ), 3.76 (s, 3H ), 3.57 (br s, 1H), 3 .45—3.10 (m, 2H ), 3.00  
(t, J  = 5.0 Hz, 2H ), 2 .88—2.77 (m, 2H ), 2.02 (m, 2H ), 1.61 (br s, 
3H ). 19F NM R (282  MHz, CDCl3, S): —166.5 (s, 1F). 13C NM R (75  
MHz, CDCl3, S): 167.9, 154.0, 152.9, 135.7, 134.1, 133.0, 130.6,
129.1, 126.2, 115.5 (2C ), 114.6 (2 C ), 94.3 (d, J  = 172 Hz), 68.0, 57.3 
(d, J  = 22 H z), 55.7, 49.4, 43.6, 38.2, 33.5, 32.5. Formula: 
C22H 25Cl2FN 2O3; MS (ESI+) m /z: 455 [M + H+].
2-(2-(((1-(3-C hloro-4-fluom benzoyl)-4-fluoropiperid in-4-yl)-  
m ethyl)am ino)ethoxy)benzam ide (42). The title compound was 
prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4- 
y l)-2-h yd roxyaceton itrile  ( 4 ) ( 0 .1 6 3  g, 0 .5 2  m m ol), 2 - (2 -  
aminoethoxy)benzamide (1 5 )  (0 .140  g, 0.78 mmol), DABCO  
(0.725 g, 6.48 mmol), sodium cyanoborohydride (0.253 g, 4.04  
mmol), molecular sieves (0.900 g), and iron sulfate heptahydrate 
(0.158 g, 0.57 mmol) in methanol (5  m L). Purification: n-hexane/ 
E t2O /D C M /m eth an o l/N H 3(aq) ( 3 /2 /4 .5 /0 .5 /0 .0 2 ,  v /v /v /v /v ) .  
Yield: 29%; white powder. 1H N M R (300  MHz, DMSO-d6, s ): 
7.95 (s, 1H), 7.81 (dd, J  = 1 .8 , 7.6 Hz, 1H), 7.65 (dd, J  = 1 .8 , 7.0 Hz, 
1H), 7.54 (br s, 1H), 7 .50—7.37 (m, 3H ), 7.12 (d, J  = 8.2 Hz, 1H),
7.00 (t, J  = 7.9 Hz, 1H), 4 .3 3 —4.07 (m, 3H ), 3.38 (br s, 1H), 3 .27—
2.97 (m, 2H ), 2.93 (t, J  = 5.3 Hz, 2H ), 2 .81—2.66 (m, 2H ), 2.13 (br s, 
1H), 1.96—1.64 (m, 4H ). 13C NM R ( 7 5  MHz, DMSO-d6, S): 167.2,
166.7, 157.2, 158.1 (d, J  = 248.7 Hz), 134.4, 132.9, 131.3, 129.7,
128.2 (d, J  = 6.9 Hz), 123.1, 121.0, 120.2 (d, J  = 18.3 Hz), 117.4 (d, J  
= 21 H z), 113.8, 95.6 (d, J  = 172 Hz), 68.5, 56.7 (d, J  = 22 Hz), 49.0,
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43.4, 38.0, 33.1, 32.3. Formula: C22H 24ClF2N 3O3; MS (ESI+) m /z: 
452  [M + H+]. mp 180.5—181.0 °C.
3-(2-(((1-(3-C hloro-4-fluorobenzoyl)-4-fluoropiperid in-4-yl)-  
m ethyl)am ino)ethoxy)benzam ide (43). The title compound was 
prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4- 
yl)-2-hydroxyacetonitrile ( 4 )  (0 .1 0 0  g, 0 .3 2  m m ol), 3 -(2 -  
aminoethoxy)benzamide (1 6 )  (0 .080  g, 0.41 mmol), DABCO  
(0 .444 g, 3 .97  mmol), sodium cyanoborohydride (0.155 g, 2.48 
mmol), molecular sieves (0.900 g), and iron sulfate heptahydrate 
(0 .097 g, 0.35 mmol) in methanol (5 m L). Purification: EtO A c/ 
methanol (9 /1 , v /v ). Yield: 42%; yellow transparent oil. 1H NM R  
(300  MHz, CDCl3, 5 ): 7.46 (dd, J  = 1.8, 7.0 Hz, 1H), 7 .42—7.37 (m, 
1H), 7 .35—7.23 (m, 3H ), 7 .20—7.11 (m, 1H), 7.04 (td, J  = 2.9, 5.9 
Hz, 1H), 6 .43—6.04 (m, 2H ), 4.49 (br s, 1H), 4 .09  (t, J  = 5.3 Hz, 
2H ), 3.58 (br s, 1H), 3 .45—3.08 (m, 2 h ) , 3 .02 (t, J  = 5.3 Hz, 2H ),
2.83 (d, J  = 19.9 Hz, 2H ), 1.98 (br s, 3H ), 1.81 — 1.48 (m, 2H ). 19F 
N M R (282 MHz, CDCl3, 5 ): —112.6 (s, 1F), —166.4 (s, 1F). 13C 
N M R (75 MHz, CDCl3, 5 ): 169.4, 168.1, 159.0, 158.8 (d, J  = 254  
H z), 134.8, 132.8 (d, J  = 3.5 Hz), 129.7, 129.6, 127.1 (d, J  = 7.7 Hz),
121.5 (d, J  = 17.3 Hz), 119.5, 118.6, 116.8 (d, J  = 22 Hz), 113.3, 94.3 
(d, J  = 172 Hz), 67.5, 57.2 (d, J  = 22 Hz), 49.1, 43.7, 38.3, 33.6, 32.8. 
Formula: C 22H 24ClF2N 3O3; MS (ESI+) m /z: 452 [M  + H+].
(3-C h loro-4-fluorophenyl)(4-fluoro-4-(((2-(2-(m ethylam ino)-  
phenoxy)ethyl)amino)m ethyl)piperidin-1-yl)m ethanone (44). The 
title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)- 
4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (4 )  (0 .120  g, 0.38  
mmol), 2-(2-aminoethoxy)-N-methylaniline (2 4 )  (0 .076 g, 0.46  
mmol), DABCO (0 .084  g, 0.76 mmol), sodium cyanoborohydride 
(0.038 g, 0.61 mmol), molecular sieves (0.900 g), and iron sulfate 
heptahydrate (0.117 g, 0.42 mmol) in methanol (5 m L). Purification: 
EtOAc/methanol (9 .5 /0 .5 , v /v ). Yield: 29%; yellow transparent oil. 
1H NM R (300  MHz, CDCl3, 5 ) : 7 .52—7.44 (m, 1H), 7 .34—7.26 (m, 
1H), 7 .23—7.12 (m, 1H), 6 .96—6.87 (m, 1H ), 6.78 (dd, J  = 1.5, 7.9  
Hz, 1H ), 6 .64  (dq, J  = 1.8, 7.8 Hz, 2H ), 4.50 (br s, 1H), 4.09 (t, J  =
5.3 Hz, 2H ), 3.60 (br s, 1H), 3 .45—3.13 (m, 2H ), 3.05 (t, J  = 5.0 Hz, 
2H ), 2 .90—2.75 (m, 5H ), 2.00 (br s, 3H ), 1.64 (m., 3H ). 19F NM R  
(282  MHz, CDCl3, 5 ): —112.6 (s, 1F), —166.6 (s, 1F). 13C NM R  
(126  MHz, CDCl3, 5 ): 168.2, 158.9 (d, J  = 252.3 Hz), 145.9, 139.7,
132.9 (d, J  = 4 .2 Hz), 129.8, 127.2 (d, J  = 7.8 Hz), 122.1, 121.7 (d, J  =
18.1 H z), 116.9 (d, J  = 21.1 H z), 116.4, 111.1, 109.8, 94.3 (d, J  =
172.6 Hz), 67.6 (s), 57.1 (d, J  = 21.7 Hz), 49.4, 43.6, 38.2, 33.6, 32.9,
30.4. Formula: C22H 26ClF2N 3O2; MS (ESI+) m /z: 438 [M + H+].
(3-C h loro-4-fluorophenyl)(4-fluoro-4-(((2-(3-(m ethylam ino)-
phenoxy)ethyl)amino)m ethyl)piperidin-1-yl)m ethanone (45). The 
title compound was prepared by Boc-deprotection of tert-butyl (3-(2- 
(((1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)m ethyl)- 
amino)ethoxy)phenyl)(methyl)carbamate (2 7 ).
Compound 2 7  (1 .0  equiv, 0.075 g, 0 .14  mmol) was mixed with 1.0 
M  HCl in EtOAc (5 mL) and stirred at room temperature for 24  h. 
Then, the mixture was filtered to give the product as a hydrochloride 
salt. The obtained hydrochloride salt was turned into a free base 
(using 10% aqueous solution of sodium carbonate) before 
purification. Purification: D CM /m ethanol/N H 3(aq) (9 .5 /0 .5 /0 .0 2 , v / 
v/v). Yield: 48%; white-gray crystallizing oil. 1H N M R (300  MHz, 
CD3OD, 5 ): 7 .73—7.00 (m, 7H ), 4.46 (br s, 3H ), 3 .77—3.34 (m, 6H ), 
3.22 (br s, 1H), 3.08 (s, 3H ), 2 .19—1.81 (m, 4H ), NH protons not 
detected. 19F NM R (282  MHz, CDCl3, 5 ): —114.8 (s, 1F), —166.6 (s, 
1F). 13C NM R (75 MHz, CDCl3, 5 ): 169.0, 160.0 (d, J  = 3.5 Hz),
156.1, 150.7 (d, J  = 4.7 Hz), 129.7 (d, J  = 8.5 H z), 129.3, 128.8,
127.1, 122.5, 111.6, 105.9, 102.8, 98.9, 94.5 (d, J  = 172 Hz), 67.0, 57.3 
(d, J  = 22 Hz), 56.2, 49.4, 43.9, 38.4, 33.7, 32.9. Formula: 
C22H 26ClF2N 3O2; MS (ESI+) m /z: 438 [M + H+].
(3-Chloro-4-fluorophenyl)(4-(((2-(3-(dim ethylam ino)phenoxy)-  
ethyl)amino)methyl)-4-fluoropiperidin-1-yl)methanone (46). The 
title compound was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)- 
4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (4 )  (0 .166  g, 0.53  
mmol), 3-(2-aminoethoxy)-N,N-dimethylaniline (1 8 ) (0.133 g, 0.74  
mmol), DABCO (0 .740 g, 6.61 mmol), sodium cyanoborohydride 
(0 .277 g, 4.13 mmol), molecular sieves (1.043 g), and iron sulfate 
heptahydrate (0.162 g, 0.58 mmol) in methanol (5 m L). Purification:
D CM /m ethanol/N H 3(aq) (9 .5 /0 .5 /0 .0 2 , v /v /v ) and then n-hexane/ 
EtOAc/methanol/NH3(3a(qa)q) (4 /5 .5 /0 .5 /0 .0 2 , v /v /v /v ). Yield: 42%; 
colorless oil. 1H NM R (300  MHz, CDCl3, 5 ): 7.48 (dd, J  = 2.1, 6.7 
Hz, 1H), 7 .34—7.25 (m, 1H), 7 .22—7.07 (m, 2H ), 6 .40—6.32 (m, 
1H), 6 .31—6.22 (m, 2 h ) ,  4 .50  (br s, 1H), 4 .06  (t, J  = 5.0 Hz, 2H ),
3.60 (br s, 1H), 3 .47—3.08 (m, 2H ), 3.02 (t, J  = 5.0 Hz, 2H ), 2.93 (s, 
6H ), 2 .84  (d, J  = 19.9 Hz, 2H ), 2.00 (br s, 2H ), 1.87—1.47 (m, 3H ). 
13C N M R (75 MHz, CDCl3, 5 ): 168.0, 159.8, 158.8 (d, J  = 254  Hz),
152.0, 132.9 (d, J  = 4 .4  Hz), 129.7 (d, J  = 2.3 Hz, 2C ), 127.1 (d, J  =
6.9 Hz), 121.5 (d, J  = 18.4 Hz), 116.8 (d, J  = 22 Hz), 105.9, 101.9,
99.6, 94.4 (d, J  = 172 Hz), 67.0, 57.3 (d, J  = 2 2  Hz), 49.4, 43.7, 40.6  
(2C ), 38.1, 33.7, 32.9. Formula: C23H 28ClF2N 3O2; MS (ESI+) m /z: 
452  [m  + H+].
N -(3-(2-(((1-(3-Chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)- 
m ethyl)am ino)ethoxy)phenyl)acetam ide (47). The title compound 
was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperi- 
din-4-yl)-2-hydroxyacetonitrile (4 )  (0 .150 g, 0.48 mmol), N -[3-(2- 
aminoethoxy)phenyl]acetamide (1 9 ) (0.148 g, 0.76 mmol), DABCO 
(0 .669 g, 5.97 mmol), sodium cyanoborohydride (0 .234  g, 3.73 
mmol), molecular sieves (1.043 g), and iron sulfate heptahydrate 
(0 .146 g, 0.53 mmol) in methanol (5 m L). Purification: EtO A c/ 
methanol (9 .5 /0 .5 , v /v ). Yield: 82%; colorless oil. 1H NM R (500  
MHz, CDCl3, 5 ): 7 .54  (br s, 1H), 7.47 (dd, J  = 1.9, 7.0 Hz, 1H), 
7.31—7.26 (m, 2H ), 7 .20—7.13 (m, 2H ), 6 .94 (br d, J  = 8.0 Hz, 1 h ), 
6.62 (br d, J  = 7.2 Hz, 1H), 4.50 (br s, 1H), 4 .1 3 —4.06 (m, 2 h ) ,  3.59 
(br s, 1H), 3 .43—3.19 (m, 2H ), 3.09 (br s, 2H ), 2.93 (br d, J  = 19.8 
Hz, 2H ), 2.14 (s, 3H ), 2.11 — 1.91 (m, 3 h ) ,  1.83—1.58 (m, 2H ). 13C 
NM R (75 MHz, CDCl3, 5 ): 173.0, 168.7, 168.1, 159.2, 158.7 (d, J  = 
254  Hz), 139.4, 132.8 (d, J  = 4 .4  Hz), 129.6 (d, J  = 6.1 H z), 127.1 (d, 
J  = 7.7 Hz), 121.5 (d, J  = 17.7 H z), 116.8 (d, J  = 22 Hz), 112.2, 110.2,
106.4, 94.3 (d, J  = 172 Hz), 67.3, 57.2 (d, J  = 22 H z), 49.2, 43.5, 38.1,
33.4, 32.5, 22.6. Formula: C23H 26ClF2N 3O3; MS (ESI+) m /z: 466 [M  
+ H+].
N -(3 -(2 -(((1 -(3 ,4 -D ich lo ro b en z o y l)-4 -flu o ro p ip erid in -4 -y l)-  
m ethyl)am ino)ethoxy)phenyl)acetam ide (48). The title compound 
was prepared using 2-(1-(3,4-dichlorobenzoyl)-4-fluoropiperidin-4- 
yl)-2-hydroxyacetonitrile ( 5 ) (0 .075  g, 0 .23  mm ol), N -[3-(2-  
am inoethoxy)phenyl]acetam ide ( 1 9 )  (0 .0 7 0  g, 0 .3 6  m m ol), 
DABCO (0.317 g, 2.83 mmol), sodium cyanoborohydride (0.111 g, 
1.76 mmol), and molecular sieves (0 .47  g) in methanol (3 mL). 
Purification: EtOAc/methanol (9 /1  v /v). Yield: 18%; yellow oil. 1H 
NM R (500 MHz, CDCl3, 5 ): 7.66 (br s, 1H), 7 .52—7.41 (m, 2H ), 
7.31 (br s, 1H), 7.21 (dd, J  = 1.7, 8.0 Hz, 1H), 7.15 (br t, J  = 8.2 Hz, 
1H), 6.92 (br d, J  = 7.7 Hz, 1H), 6.61 (br d, J  = 7.2 Hz, 1H), 4.50 (br 
s, 1H), 4.06 (br t, J  = 4.9 Hz, 2H ), 3.56 (br s, 1H ), 3.36 (br s, 1H), 
3.12 (br s, 1H), 3.05 (br t, J  = 4 .0 Hz, 2H ), 2.88 (br d, J  = 17.5 Hz, 
2H ), 2.60 (br s, 1H), 2.13 (s, 3H ), 2 .08—1.88 (m, 2H ), 1.66 (br s, 
2 h ) .  13C NM R (126 MHz, CDCl3, 5 ): 168.5, 168.1, 159.4, 139.3,
135.7, 134.2, 133.1, 130.7, 129.7, 129.2, 126.3, 112.2, 110.4, 106.5,
94.4 (d, J  = 172.6 H z), 67.4, 57.3 (d, J  = 22.3 Hz), 49.3, 43.7, 38.2,
33.7 (d, J  = 16.9 Hz), 32.79 (d, J  = 17.5 H z), 24.8. Formula: 
C23H 26Cl2FN 3O3; MS (ESI+) m /z: 482  [M + H+].
(3-C hloro-4-fluorophenyl)(4-fluoro-4-(((2-(m -tolyloxy)ethyl)- 
am ino)m ethyl)piperidin-1-yl)methanone (49). The title compound 
was prepared using 2-(1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperi- 
din-4-yl)-2-hydroxyacetonitrile (4 )  (0 .120 g, 0.38 mmol), 2-(m- 
tolyloxy)ethanamine (2 0 ) (0.081 g, 0.54 mmol), DABCO (0.535 g,
4.78 mmol), sodium cyanoborohydride (0.178 g, 2.98 mmol), 
molecular sieves (0.900 g), and iron sulfate heptahydrate (0.117 g, 
0.42 mmol) in methanol (5  m L). Purification: n-hexane/Et2O /D C M / 
methanol/NH3(aq) (3 /2 /4 .5 /0 .5 /0 .0 2 , v /v /v /v /v ). Yield: 153%; white 
crystallizing oil. 1^  NM R (300  MHz, CD3OD, 5): 7.59 (dd, J  = 1 .8 ,
7.0 Hz, 1H), 7 .45—7.37 (m, 1H), 7 .36—7.28 (m, 1H), 7 .17—7.06 (m, 
1H), 6 .78—6.66 (m, 3 h ), 4.43 (br s, 1H), 4.05 (t, J  = 5.3 Hz, 2H ), 
3.68—3.49 (m, 1H), 3.39 (br s, 1H), 3 .28—3.09 (m, J  = 5.3 Hz, 1h ),
3.00 (t, J  = 5.6 Hz, 2H ), 2 .91—2.79 (m, 2H ), 2.29 (s, 3H ), 2 .06—1.62 
(m, 4H ), N H  proton not detected. 13C NM R (75 MHz, CD3OD, 5):
168.6, 158.8, 158.7 (d, J  = 251 Hz), 139.2, 133.0 (d, J  = 4 .6  Hz),
129.3, 128.8, 127.3 (d, J  = 6.9 Hz), 121.3, 120.9 (d, J  = 18.4 Hz),
116.6 (d, J  = 21.8 H z), 114.9, 111.1, 93.8 (d, J  = 172.7 Hz), 66.5, 56.5
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(d, J  = 21.9 Hz), 48.8, 43.6, (8 .1 , (2 .9 , (2 .2 , 20.2. Formula: 
C22H 25ClF2N 2O2; MS (ESIł ) m /z: 4 2 (  [M ł  Hł ].
(3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-(3-(trifluorom ethyl)- 
phenoxy)ethyl)amino)m ethyl)piperidin-1-yl)m ethanone (SC). The 
title compound was prepared using 2-(l-(3-chloro-4-fluorobenzoyl)-
4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (4 )  (0 .150  g, 0.48  
mmol), 2-(3-(trifluoromethyl)phenoxy)ethanamine (2 1 ) (0 .156 g, 
0.76 mmol), DABCO (0.669 g, 5.97 mmol), sodium cyanoborohy­
dride (0 .2 (4  g, ( .7 3  mmol), molecular sieves (1.043 g), and iron 
sulfate heptahydrate (0 .146 g, 0.53 mmol) in methanol (5 mL). 
Purification: EtOAc/methanol (9 .5 /0 .5 , v /v ) and then n-hexane/ 
EtOAc (3 /7 , v /v ). Yield: 49%; yellow transparent oil. 1H NM R (300  
MHz, CDCl(, S): 7.48 (dd, J  = 2.1, 6.7 Hz, 1H), 7 .42—7.34 (m, 1H), 
7.33—7.26 (m, 1H), 7 .24—7.16 (m, 2H ), 7.13 (d, J  = 3.5 Hz, 1 h ),
7.06 (dd, J  = 2.9, 8.2 Hz, 1H), 4.48 (br s, 1H), 4.09 (t, J  = 5.0 Hz, 
2H ), 3 .75—3.48 (m, 1H), 3 .47—3.10 (m, 2H ), 3.05 (t, J  = 5.0 Hz, 
2 h ) ,  2 .91—2.76 (m, 2 h ) ,  2 .07—1.95 (m, 2 h ) ,  1.83—1.44 (m, 3H ). 
13C N M R (75 MHz, CDCl(, S): 168.1, 158.9, 158.8 (d, J  = 254  Hz),
132.9 (d, J  = 4 .6  Hz), 131.8 (d, J  = 32.3 Hz), 130.0, 129.7, 127.1 (d, J  
= 8.1 Hz), 123.9 (q, J  = 272 Hz), 121.5 (d, J  = 18.2 Hz), 117.9, 117.6 
(q, J  = 3.9 Hz), 116.8 (d, J  = 22 Hz), 111.3 (q, J  = 3.9 H z), 94.3 (d, J  
= 172 Hz), 67.7, 57.3 (d, J  = 2 2  H z), 49.1, 43.5, 38.3, 33.7, 32.8. 
Formula: C 22H 22ClF5N 2O2; MS (ESI+) m /z: 477 [M  4  H+].
(3-C hloro-4-fluorophenyl)(4-fluoro-4-(((2-(quinolin-8-yloxy)- 
ethyl)am ino)m ethyl)piperidin-1-yl)m ethanone (Sí). The title com­
pound was prepared using 2-(l-(3-chloro-4-fluorobenzoyl)-4-fluoro- 
piperidin-4-yl)-2-hydroxyacetonitrile (4 )  (0 .200 g, 0.64 mmol), 2- 
(quinolin-8-yloxy)ethanamine (2S) (0.192 g, 1.02 mmol), DABCO 
(0.8 92  g, 7.96 mmol), sodium cyanoborohydride (0.311 g, 4.99  
mmol), molecular sieves (1.400 g), and iron sulfate heptahydrate 
(0.195 g, 0.70 mmol) in methanol (7  m L). Purification: EtO A c/ 
methanol (9 .5 /0 .5 , v /v ). Yield: 69%; beige crystallizing oil. 1H NM R  
(300  MHz, CDCl(, S): 8.92 (dd, J  = 1.8, 4.1 Hz, 1H ), 8.15 (dd, J  =
1.7, 8.3 Hz, 1H), 7 .50—7.38 (m, 4H ), 7.28 (dd, J  = 2.1, 4.6 Hz, 1H), 
7.19—7.12 (m, 1H), 7.09 (dd, J  = 1.7, 7.3 Hz, 1H), 4.50 (br s, 1 h ), 
4.34 (t, J  = 5.3 Hz, 2H ), 3.58 (br s, 1H), 3 .39—3.13 (m, 4H ), 2 .98— 
2.86 (m, 2H ), 2 .06—1.97 (m, 2H ), 1.66 (br s, 3H ). 13C NM R (75  
MHz, CDCl(, S): 168.0, 158.7 (d, J  = 254 Hz), 154.5, 149.2, 140.2,
136.1, 132.9 (d, J  = 4 .4 Hz), 129.7, 129.5, 127.1 (d, J  = 7.2 Hz),
126.7, 121.7, 121.4, 120.1, 116.7 (d, J  = 22 Hz), 109.4, 94.3 (d, J  = 
172 Hz), 68.7, 57.3 (d, J  = 22 Hz), 49.1, 43.6, 38.3, 33.6, 32.9. 
Formula: C 24H 24ClF2N 3O2; MS (ESI+) m /z: 460 [M  4  H+].
(3 ,4-D ichlorophenyl)(4-fluoro-4-(((2-(quinolin-8-yloxy)ethyl)- 
am ino)m ethyl)piperidin-1-yl)methanone Fum arate Salt (S2). The 
title compound was prepared using 2-(l-(3,4-dichlorobenzoyl)-4- 
fluoropiperidin-4-yl)-2-hydroxyacetonitrile (S) (0 .597 g, 1.90 mmol),
2-(quinolin-8-yloxy)ethanamine (2S) (0.395 g, 2.11 mmol), DABCO 
(2 .660 g, 23.75 mmol), sodium cyanoborohydride (0 .932 g, 14.82 
mmol), and molecular sieves (3.200 g) in methanol (18  mL). 
Purification: EtO A c/m ethanol/N H ((aq) (9 .5 /0 .5 /0 , 02, v /v /v ). Yield: 
15%; white oil. The compound was prepared as fumarate salt by 
adding a solution on fumaric acid in methanol (0 .034  g in 2 mL 
methanol). 1H NM R (500  MHz, CD(OD, S): 8.88 (dd, J  = 1.7, 4.3 
Hz, 1H), 8.37 (dd, J  = 1 .6 , 8.4 Hz, 1H), 7 .64—7.51 (m, 5H ), 7.34 (dd, 
J  = 2.0, 8.3 Hz, 1H), 7 .27—7.22 (m, 1H), 6.66 (s, 2H ), 4.53 (br s, 
1H), 4 .49  (t, J  = 4.8 Hz, 2H ), 3 .68—3.54 (m, 3H ), 3 .50—3.37 (m, 
3H ), 3.20 (br s, 1H), 2 .23—1.74 (m, 4H ), NH protons not detected. 
13C NM R (126  MHz, CD(OD, S): 169.6 (2 C ), 168.5, 152.9, 148.9,
138.8, 137.3, 135.6, 134.8 (2 C ), 133.9, 132.6, 130.8, 129.8, 128.9,
127.1, 126.4, 122.0, 120.6, 109.3, 91.8 (d, J  = 175.6 Hz), 63.4, 53.9 (d, 
J  = 21.1 Hz), 47.2, 42.9, 37.5, 32.5 (d, J  = 19.3 Hz), 31.8 (d, J  = 26.6 
H z). Formula: C24H 24Cl2FN 3O2-C4H4O4; MS (ESI+) m /z: 476  [M  ł
h +].
(3 -C h lo ro -4-flu o ro p h en y l)(4-(((2-((2 ,3-d ih y d rob en zo[b ][1 ,4 ]-  
d io x in -5-y l)o xy )eth y l)a m in o )m eth y l)-4-flu o ro p ip erid in -1-y l)-  
m ethanone (SS). The title compound was prepared using 2 -(l -(3 -  
chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile 
(4 )  (0.081 g, 0.26 mmol), 2 -(2 , 3-dihydro-l, 4-benzodioxin-6- 
yloxy)ethanamine (2 2 )  (0 .080 g, 0.41 mmol), DABCO (0 .359 g, 
3.20 mmol), sodium cyanoborohydride (0.125 g, 2.00 mmol), and
molecular sieves (0.531 g) in methanol (3 m L). Purification: EtO A c/ 
methanol (9 .5 /0 .5 , v/v).Yield: 19%, colorless oil. 1H NM R (300  
MHz, CDCl(, S): 7.48 (dd, J  = 2.1, 6.9 Hz, 1H), 7 .32—7.26 (m, 1H), 
7.21—7.14 (m, 1H), 6 .78—6.71 (m, 1H), 6.53 (ddd, J  = 1.3, 8.2, 10.8 
Hz, 2H ), 4.50 (br s, 1H), 4 .3 2 —4.27 (m, 2H ), 4 .27—4.23 (m, 2H ), 
4 .16—4.07 (m, 2H ), 3.60 (br s, 1H), 3.34 (br s, 2H ), 3.05 (t, J  = 5.3 
Hz, 2H ), 2 .91—2.78 (m, 2H ), 2.02 (s, 2H ), 1.63 (br s, 3H ). Formula: 
C23H 25ClF2N 2O4; MS (ESIł ) m /z: 467  [M ł  Hł ].
2(3,425-Dic2hlo2ro4phenyl)(4-(((2-((2,3-dihydrobenzo[b][1,4]dioxin-5- 
y l)o xy )eth y l)a m in o )m eth yl)-4-flu o ro p ip erid in -1-y l)m eth a n o n e  
(S4). The title compound was prepared using 2-(l-(3,4-chloroben- 
zoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (S) (0 .200 g, 0.60 
mm ol), 2-(2,3-dihydro-1,4-benzodioxin-6-yloxy)ethanamine (2 2 )  
(0 .189 g, 0.97 mmol), DABCO (0 .847 g, 7.55 mmol), sodium 
cyanoborohydride (0.296 g, 4.71 mmol), and molecular sieves (1.254  
g) in methanol (6  m L). Purification: EtOAc/methanol (9 .9 /0 .1 , v /v) 
and then n-hexane/EtOAc/methanol/NH3(aq) (4 /5 .5 /0 .5 /0 .0 2 , v /v /  
v/v). Yield: 30%; pale yellow oil. 1H NM R (300  MHz, CDCl3, S):
7 .53—7.46 (m, 2H ), 7.23 (dd, J  = 1.8, 8.2 Hz, 1H), 6 .78—6.71 (m, 
1H), 6.52 (ddd, J  = 1 .4 , 8.3, 10.8 Hz, 2H ), 4.51 (br s, 1H), 4 .31—4.27  
(m, 2H ), 4 .27—4.23 (m, 2H ), 4.11 (t, J  = 5.4 Hz, 2H ), 3.56 (br s, 
1H), 3 .45—3.11 (m, 2H ), 3.04 (t, J  = 5.1 Hz, 2H ), 2 .90—2.79 (m, 
2 h ) ,  2 .08—1.92 (m, 2 h ) ,  1.67 (br s, 3H ). 19F NM R (282  MHz, 
CDCl(, S): —166.3 (s, 1F). 13C NM R (75 MHz, CDCl(, S): 167.9,
148.2, 144.4, 135.7, 134.1, 133.9, 133.0, 130.6, 129.1, 126.2, 120.2,
110.5, 106.3, 95.5 (d, J  = 172 Hz), 69.0, 64.4, 64.2, 57.3 (d, J  = 22  
H z), 49.2, 43.5, 39.0, 33.6, 32.6 Formula: C 23H 25Cl2FN 2O4; MS 
(ESI+) m /z: 483 [M  ł  H+].
(3-Chloro-4-fluorophenyl)(4-(((2-((2,2-dim ethyl-2,3-dihydroben- 
z o fu ra n -7-yl)oxy)ethyl)am ino)m ethyl)-4-fluoropiperid in-1-yl)-  
m ethanone (SS). The title compound was prepared using 2 -(l -(3 -  
chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile
(4 ) (0 .100 g, 0.32 mmol), 2-((2,2-dimethyl-2,3-dihydrobenzofuran-7- 
yl)oxy)ethanamine (2S) (0.092 g, 0.45 mmol), DABCO (0 .444 g,
3.97 mmol), sodium cyanoborohydride (0.155 g, 2.48 mmol), 
molecular sieves (0.900 g), and iron sulfate heptahydrate (0.097 g, 
0.35 mmol) in methanol (5 m L). Purification: n-hexane/DCM / 
methanol/NH3(aq) (4 /5 .5 /0 .5 /0 .0 2 , v /v /v /v ). Yield: 33%; yellow oil. 
1H NM R (300  MHz, CDCl(, S): 7.48 (dd, J  = 1 .8 , 7.0 Hz, 1H), 7 .32— 
7.25 (m, 1H ), 7 .22—7.13 (m, 1H), 6 .81—6.70 (m, 3H ), 4.50 (br s, 
1H), 4.15 (t, J  = 5.0 Hz, 2H ), 3 .71—3.50 (m, 1H), 3 .48—3.08 (m, 
2 h ) ,  3 .06—2.96 (m, 4H ), 2.83 (d, J  = 19.9 Hz, 2H ), 1.99 (br s, 2H ),
1.83 (br s, 3H ), 1.49 (s, 6H ). 13C NM R (75  MHz, CDCl(, S): 168.0,
158.8 (d, J  = 254 H z), 147.9, 143.5, 132.9 (d, J  = 3.5 Hz), 129.7,
128.6, 127.1 (d, J  = 8.1 Hz), 121.5 (d, J  = 18.4 Hz), 120.3, 118.1,
116.8 (d, J  = 2 2  Hz), 113.7, 94.3 (d, J  = 1 7 2  Hz), 87.3, 69.0, 57.2 (d, J  
= 22 Hz), 49.2, 43.6, 43.2, 38.3, 33.5, 32.8, 28.3 (2 C ). Formula: 
C25H 29ClF2N 2O3; MS (ESIł ) m /z: 479  [M ł  Hł ].
(4-(((2-((1 H-Indol-4-yl)oxy)ethyl)amino)methyl)-4-fluoropiperi- 
din-1-yl)(3-chloro-4-fluorophenyl)m ethanone Fum arate Salt (S6). 
The title compound was prepared using 2-(l-(3-chloro-4-fluoroben- 
zoyl)-4-fluoropiperidin-4-yl)-2-hydroxyacetonitrile (4 )  (0 .150 g, 0.48 
mmol), 2-((lH -indol-4-yl)oxy)ethanam ine (2 é )  (0 .126  g, 0.72  
mmol), DABCO (0 .669 g, 5.97 mmol), sodium cyanoborohydride 
(0 .234 g, 3.73 mmol), molecular sieves (1.043 g), and iron sulfate 
heptahydrate (0.146 g, 0.53 mmol) in methanol (5 m L). Purification: 
n-hexane/EtO A c/m ethanol/N H 3(aq) ( 3 /6 .5 /0 .5 /0 .0 2 ,  v /v /v /v ) .  
Yield: 64%; beige powder. The compound was prepared as fumarate 
salt by adding a solution on fumaric acid in methanol (0.035 g in 2 
mL methanol). 1H NM R (500  MHz, CD(OD, S): 7.58 (dd, J  = 2.0,
7.2 Hz, 1H), 7 .40—7.35 (m, 1H), 7 .35—7.30 (m, 1H ), 7 .14 (d, J  = 3.2 
Hz, 1H), 7 .08—6.99 (m, 2H ), 6.71 (s, 2H ), 6.58 (d, J  = 2.9 Hz, 1H), 
6.54 (d, J  = 7 .4 Hz, 1H), 4.49 (br s, 1H), 4.43 (t, J  = 5.2 Hz, 2 h ),
3.60 (br s, 1H), 3.56 (t, J  = 5.0 Hz, 2H ), 3 .48—3.35 (m, 3H ), 3.19 (br 
s, 1 h ), 2.09 (br s, 1 h ), 1.98 (s, 2H ), 1.91 — 1.72 (m, 2H ), NH protons 
not detected. 13C NM R (126  MHz, CD(OD, s ) :  170.0 (2C ), 169.6,
159.8 (d, J  = 251.1 Hz), 152.2, 138.9, 135.5 (2C ), 133.7 (d, J  = 4.2 
H z), 130.4, 128.3 (d, J  = 7.8 H z), 123.9, 122.5, 121.9 (d, J  = 18.1 Hz),
119.6, 117.7 (d, J  = 22.3 Hz), 106.4, 100.9, 99.1, 92.9 (d, J  = 175.0
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H z), 64.1, 55.1 (d, J  = 20.5 Hz), 48.9, 43.9, 38.5, 33.3, 32.6. Formula: 
C23H24ClF2N 3O2-C4H4O4j MS (ESI+) m /z: 448 [M  + H+].
(3-Chloro-4-fluorophenyl)(4-fluoro-4-(((2-(indolin-4-yloxy)ethyl)- 
am ino)m ethyl)piperidin-1-yl)methanone (57). The title compound 
was prepared by the reduction of ((4-(((2-((1H -indol-4-yl)oxy)- 
e th y l)a m in o )m e th y l) -4 -f l  u o r o p ip e r id in -1 -y l ) (3 - c h lo r o -4 -  
fluorophenyl)methanone) (5 6 ).
To a solution of compound 5 6  (1 .0  equiv, 0 .177 g, 0.40 mmol) in 
acetic acid ( 1.0  equiv, 0.23 mL, 0.40 mmol) sodium cyanoborohy- 
dride (2 .0  equiv 0.051 g, 0.80 mmol) was added in portions at 15 °C. 
Then, the mixture was warmed up to room temperature and stirred 
for an hour. The reaction mixture was then cooled to 0 °C, quenched, 
and adjusted to pH 8 with a saturated aqueous solution of sodium 
bicarbonate and extracted with EtOAc (3 X ). The organic layers were 
combined and dried over magnesium sulfate, filtered, and 
concentrated to yield the crude product that was purified by flash 
chromatography in n-hexane/EtOAc/methanol/NH 3(aq) (6 /3 /1 /0 .0 2 ,  
v /v /v /v ). Yield: 67%; pale pink transparent oil. 1H NM R (300  MHz, 
CDCl3, 5 ): 7.48 (dd, J  = 2.3, 7.0 Hz, 1H), 7 .3 5 -7 .2 6  (m, 1H), 7 .23­
7.11 (m, 1H), 6.97 (t, J  = 7.9 Hz, 1H), 6.29 (dd, J  = 7.9, 14.4 Hz, 
2H ), 4.51 (br s, 1H), 4.08 (t, J  = 5.0 Hz, 2H ), 3.56 (t, J  = 8.5 Hz, 
3H ), 3 .4 7 -3 .0 8  (m, 2H ), 3 .0 6 -2 .9 3  (m, 4H ), 2 .9 1 -2 .7 6  (m, 2H ),
2.02 (br s, 2H ), 1 .8 5 -1 .4 4  (m, 2H ), N H  protons not detected. 19F 
N M R (282 MHz, C D O 3, 5 ): -1 1 2 .6  (s, 1F), -1 6 6 .7  (s, 1F). 13C 
N M R (75 MHz, C D Q 3, 5 ): 168.0, 158.8 (d, J  = 254  Hz), 155.6, 
153.5, 132.9 (d, J  = 3.5 Hz), 129.7, 128.6, 127.1 (d, J  = 6.9 Hz), 121.5 
(d, J  = 1 8  Hz), 116.8 (d, J  = 22 Hz), 116.0, 103.3, 102.6, 94.4 (d, J  = 
172 H z), 67.2, 57.2 (d, J  = 22 Hz), 49.3, 47.4, 43.5, 38.2, 33.5, 32.7, 
26.9. Formula: C23H 26ClF2N 3O2; MS (ESI+) m /z: 450 [M + H+].
In Vitro Studies. The tested compounds were examined for 
known classes of assay interference compounds. None of the 
compounds contain substructural features recognized as pan assay 
interference compounds (PAINS), according to the SwissADME 
tool.52
R ad io lig an d  B in ding A ssays fo r 5 -H T ^ R , o ,R , D2R.
Preparation o f  Solutions o f  Test a n d  R eference Compounds.
Stock solutions (1 mM ) of tested compounds were prepared in 
DMSO. Serial dilutions of compounds were prepared in a 96-well 
microplate in assay buffers using automated pipetting system 
epMotion 5070 (Eppendorf). The final concentration of DMSO in 
the test solutions was 0.1%. Each compound was tested in 10 
concentrations from 1.0 X 10 -6  to 1.0 X 10 -12  M  (final 
concentration).
Serotonin 5-HT1A Receptor Binding Assay. Radioligand binding
was performed using membranes from C H O -K 1 cells stably 
transfected with the human 5 -H T ^  receptor (PerkinElmer). All 
assays were carried out in duplicate. A working solution (50  pL) of 
the tested compounds, 50 pL  of [ 3H ]- 8 -O H -D PA T (final 
concentration 1 nM ), and 150 pL of diluted membranes (10  pg 
protein per well) prepared in assay buffer (50  mM Tris, pH 7.4, 10 
mM MgSO4, 0, 5 mM EDTA, 0.1% ascorbic acid) were transferred to 
a polypropylene 96-well microplate using a 96-well pipetting station 
Rainin Liquidator (MettlerToledo). Serotonin (10  pM ) was used to 
define nonspecific binding. The microplate was covered with a sealing 
tape, mixed, and incubated for 60 min at 27 °C. The reaction was 
terminated by rapid filtration through a G F/C  filter mate presoaked 
with 0.3% polyethyleneimine for 30 min. Ten rapid washes with 200  
pL 50 mM Tris buffer (4  °C, pH 7.4) were performed using an 
automated harvester system Harvester-96 MACH III FM (Tom tec). 
The filter mates were dried at 37 °C in forced air fan incubator and 
then solid scintillator MeltiLex was melted on filter mates at 90 °C  for 
4  min. Radioactivity was counted in MicroBeta2 scintillation counter 
(PerkinElmer). Data were fitted to a one-site curve-fitting equation 
with Prism 6  (GraphPad Software) and K  values were estimated from 
the Cheng-Prusoff equation.
A drenergic  a ,  Receptor Binding Assay. Radioligand binding was 
performed using rat cortex. Tissue was homogenized in 20 volumes of 
ice-cold 50 mM Tris-HCl buffer, pH 7.6, using an Ultra Turrax T25B  
(IKA) homogenizer. The homogenate was centrifuged at 20,000g for 
20 min. The resulting supernatant was decanted and the pellet was
resuspended in the same buffer and centrifuged again in the same 
conditions. The final pellet was resuspended in an appropriate volume 
of buffer (10  m g/1 m L). All assays were carried out in duplicate. The 
working solution (50  p L) of the tested compounds, 50 pL of [3H]- 
prazosin (final concentration 0.2 nM ), and 150 pL of tissue 
suspension were transferred to a polypropylene 96-well microplate 
using a 96-well pipetting station Rainin Liquidator (MettlerToledo). 
Phentolamine (10  pM ) was used to define nonspecific binding. The 
microplate was covered with a sealing tape and the content mixed and 
incubated for 30 min at 30 °C. The incubation was terminated by 
rapid filtration over glass fiber filters FilterMate B  (PerkinElmer, 
USA) using a 96-well FilterMate harvester (PerkinElmer, USA). Five 
rapid washes were performed with ice-cold 50 mM Tris-HCl buffer, 
pH 7.6. The filter mates were dried at 37 °C in a forced air fan 
incubator and then solid scintillator MeltiLex was melted on filter 
mates at 90 °C for 5 min. Radioactivity was counted in a MicroBeta2 
scintillation counter (PerkinElmer). Data were fitted to a one-site 
curve-fitting equation with Prism 6  (GraphPad Software) and Ki 
values were estimated from the Cheng-Prusoff equation.
D opam ine D2 Receptor Binding Assay. Radioligand binding was 
performed using membranes from CHO-K1 cells stably transfected 
with the human D 2 receptor (PerkinElmer). All assays were carried 
out in duplicate. A working solution (50  pL) of the tested 
compounds, 50 pL of [3H]-methylspiperone (final concentration 
0.4 nM ), and 150 pL of diluted membranes (3 pg protein per well) 
prepared in assay buffer (50  mM Tris, pH 7.4, 50 mM HEPES, 50  
mM NaCl, 5 mM MgCl2, 0.5 mM EDTA) were transferred to a 
polypropylene 96-well microplate using a 96-well pipetting station 
Rainin Liquidator (MettlerToledo). Haloperidol (10  pM ) was used to 
define nonspecific binding. The microplate was covered with a sealing 
tape, and the mixture was mixed and incubated for 60 min at 37 °C. 
The reaction was terminated by rapid filtration through a G F/B  filter 
mate presoaked with 0.5% polyethyleneimine for 30 min. Ten rapid 
washes with 200 pL of 50 mM Tris buffer (4  °C, pH 7.4) were 
performed using an automated harvester system Harvester-96 MACH  
III FM  (Tom tec). The filter mates were dried at 37 °C  in a forced air 
fan incubator and then solid scintillator MeltiLex was melted on filter 
mates at 90 °C for 5 min. Radioactivity was counted in a MicroBeta2 
scintillation counter (PerkinElmer). Data were fitted to a one-site 
curve-fitting equation with Prism 6  (GraphPad Software) and Ki 
values were estimated from the Cheng-Prusoff equation.
F u n ctio n a l A ssay s fo r th e  5 -H T ^  R e c e p to r . ERK1/2 
Phosphorylation. Test and reference compounds were dissolved in 
dimethyl sulfoxide (DMSO) at a concentration of 10 mM. Serial 
dilutions were prepared in a 96-well microplate in HBSS with 0.1%  
BSA added and eight concentrations were tested. The final 
concentration of DMSO in the test solutions was 0.1%.
The C H O -5H T1A receptor cells were tested for agonist-induced 
ERK1/2-phosphorylation using the SureFire ERK1/2-phosphoryla- 
tion a  LISA assay kit according to the manufacturer’s instruction 
(Perkin Elmer). After thawing, cells were cultured in medium 
[advanced D M EM /F12 with 1% fetal bovine serum (FBS) dialyzed, 
400  pg/m L G-418, 4  mM L-glutamine]. At the experiment, cells were 
plated at 50,000 cells/well of a 96-well tissue culture plate and grown 
7 h in an incubator (5% CO2, 37 °C ); after this time, the cells were 
starving (D M EM /F12 with 0, 1% BSA (immunoglobulin- and 
protease-free) for 12 h. The serial dilutions of compounds were 
added and incubated for 15 min in 37 °C. The medium was removed, 
“lysis buffer” (70  p L) was added and the plate gently agitated on a 
plate shaker (10  min). The plates were frozen at - 8 0  °C. The next 
day, the plate was thawed on plate shaker for 10 min and 10 pL was 
transferred to assay plates (384-OptiPlate, Perkin Elmer) in duplicate 
and 10 pL of the reaction mix a  LISA SureFire Ultra assay (Perkin 
Elmer) was added. The plate was incubated for 2 h at 22 °C. After 
incubation, the assay plate was measured in an EnVision multi­
function plate reader (PerkinElmer Life Science). Emav values were 
defined as the response of the ligand expressed as a percentage of the 
maximal response elicited by serotonin, determined by nonlinear 
regression using GraphPad Prism 6.0  software. pEC 50 values
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correspond to the ligand concentration at which 50% of its own 
maximal response was measured.
cAMP Inhibition. Tested and reference compounds were dissolved 
in DMSO to the concentration of 10 mM. Dilutions were prepared in 
a 96-well microplate in assay buffers. For 5 -H T ^  receptors, adenylyl 
cyclase activity was determined using cryopreserved CHO-K1 cells 
with expression of the human serotonin 5 -H T ^  receptor. The final 
concentration of DMSO in the test solutions was 0.1%.
The functional assay was performed with the CHO-K1 cells with 
expression of the 5-H T1A human serotonin receptor in which plasmid 
containing the coding sequence was transfected. The cells were 
cultured under selective conditions (400  ^g/m L Geneticin G 418) 
(PerkinElmer). Thawed cells were resuspended in stimulation buffer 
(hBSS, 5 mM HEPES, 0.5 IBMX, and 0.1% BSA at pH 7.4) at 2 X 
105 cells/mL. The same volume (10  ^L) of cell suspension was added 
to tested compounds with 10 ^M  forskolin. Samples were loaded onto 
a white opaque half-area 96-well microplate. Cell stimulation was 
performed for 40 min at room temperature. After incubation, cAMP 
measurements were performed with homogeneous time-resolved 
fluorescence resonance energy transfer (TR -FR ET ) immunoassay 
using the LANCE Ultra cAMP kit (PerkinElmer, USA). Ten  
microliters of EucAMP Tracer Working Solution and 10 ^L of 
ULight-anti-cAMP Tracer Working Solution were added, mixed, and 
incubated for 1 h. The TR-FRET signal was read on an EnVision 
microplate reader (PerkinElmer, USA). Emax values were defined as 
the response of the ligand expressed as a percentage of the maximal 
response elicited by serotonin, determined by nonlinear regression 
using GraphPad Prism 6.0 software. pEC50 values correspond to the 
ligand concentration at which 50% of its own maximal response was 
measured.
fi-Arrestin Recruitment. Test and reference compounds were 
dissolved in DMSO at a concentration of 10 mM. Serial dilutions 
were prepared in 96-well microplate in Dulbecco’s modified Eagle’s 
medium (DM EM ) with 10% FBS added and eight concentrations 
were tested. The final concentration of DMSO in the test solutions 
was 0.1%.
The HTR1A-bla U2OS receptor cells containing the human 
Serotonin Type 1A receptor linked to a TEV protease site and a Gal4- 
V P16 transcription factor were tested for agonist induced using the 
Tango LiveBLAzer assay kit according to the manufacturer’s 
instruction (Life Technologies). After thawing, cells were cultured 
in medium (M cCoy’s 5A with 10% FBS dialyzed, 0.1 mM NEAA, 25 
mM HEPES, 1 mM sodium pyruvate, 100 ^g/m L G-418, 100 U /m L  
penicillin/streptomycin antibiotic, 200 ^g/m L zeocin, 50 ^g/m L  
hygromycin). At the experiment, cells were plated at 10,000 cells/well 
of a 384-well black, clear bottom, tissue culture plate and grown for 12 
h in an incubator (5% CO 2, 37 °C ) in DMEM with 10% FBS added. 
The serial dilutions of compounds were added and incubated for 5 h 
(5% CO 2, 37 °C ). After this time, 8 ^L of reaction mix was added. 
The plate was incubated for 2 h at 22 °C. After incubation, the assay 
plate was measured in a FLUOstar Optima multifunction plate reader 
(PerkinElmer Life Science). Emax values were defined as the response 
of the ligand expressed as a percentage of the maximal response 
elicited by serotonin, determined by nonlinear regression using 
GraphPad Prism 6.0 software. pEC50 values correspond to the ligand 
concentration at which 50% of its own maximal response was 
measured.
Calcium Mobilization Assay. Test and reference compounds were 
dissolved in DMSO at a concentration of 10 mM. Serial dilutions 
were prepared in a 96-well microplate in assay buffer and 8 - 1 0  
concentrations were tested. The final concentration of DMSO in the 
test solutions was 0.1%.
A cellular aequorin-based functional assay was performed with 
recombinant CHO-K1 cells expressing mitochondrially targeted 
aequorin, human GPCR and the promiscuous G protein «16 for 5- 
H T1A receptor. Assay was executed according to a previously 
described protocol. After thawing, cells were transferred to assay 
buffer (DM EM /H AM ’s F12 with 0.1% protease free BSA) and 
centrifuged. The cell pellet was resuspended in assay buffer and 
coelenterazine h was added at a final concentration of 5 ^M. The cell
suspension was incubated at 16 °C, protected from light with constant 
agitation for 16 h, and then diluted with assay buffer to the 
concentration of 100,000 cells/mL. After 1 h of incubation, 50 ^L of 
the cell suspension was dispensed using automatic injectors built into 
the radiometric and luminescence plate counter MicroBeta2 LumiJET 
(PerkinElmer, USA) into white opaque 96-well microplates preloaded 
with test compounds. Immediate light emission generated following 
calcium mobilization was recorded for 30 s. In antagonist mode, after 
25 min of incubation, the reference agonist was added to the above 
assay mix and light emission was recorded again. The final 
concentration of the reference agonist was equal to EC 80 (300  nM 
serotonin).
D evelopability Studies. Preliminary Metabolic StabilityAssess-
m ent. The in vitro evaluation of metabolic stability of phenoxyethyl 
derivatives of 1-(1-benzoyl-4-fluoropiperidin-4-yl)methanamine was 
performed by using RLMs (Sigma-Aldrich, St. Louis, MO, USA) 
according to previously described methods and protocols.53- 55 The 
reaction mixtures were prepared first, consisting of 50 ^M  of the 
tested compound, microsomes (1 m g/m L), and 10 mM Tris-HCl 
buffer, pH = 7.4. Reaction mixtures were preliminarily incubated for 5 
min in a temperature of 37 °C. After preincubation, 50 ^L of an 
NADPH Regeneration System (Promega, Madison, WI, USA) was 
added to initiate the reaction. The reaction mixtures were incubated 
for 2 h at a temperature of 37 °C. In order to terminate the reaction, 
200 ^L of cold extrapure methanol was added. Then, the mixtures 
were centrifuged (14 ,000  rpm, 15 min) and the supernatants were 
analyzed using an LC/M S Waters ACQ UITY TQD system with the 
T Q  Detector (Waters, Milford, USA).
in silico prediction of metabolic biotransformations was performed 
by MetaSite 6.0.1 software (Molecular Discovery Ltd, Hertfordshire, 
UK).56 The computational liver model of metabolism was used for 
determination of the most probable sites of metabolism and 
identification of structures of obtained in vitro metabolites.
Intrinsic Clearance. For determination of the intrinsic clearance 
(C Lint) parameter, five independent reactions were terminated by the 
addition of cold methanol containing IS at different time points: 0, 5, 
15, 30, 45 min. The reaction mixtures were next centrifuged at 14,500  
rpm for 10 min. The course of reaction was followed by using the 
analyte/IS peak height ratio values. In the determination of the in vitro 
t1/2 value, the slope of linear regression from log concentration 
remaining versus time relationships ( - k) was used according to 
Obach (1999). The supernatants with 3, 44, and 56 were analyzed by 
an H PLC system (LaChrom  Elite, Merck-Hitachi, Germany) 
consisting of an L-2130 pump, an L -2200 autosampler, and an L- 
2420 U V -V IS detector. EZChrome Elite v. 3.2 (Merck-Hitachi, 
Germany) computer program was used for data acquisition and 
integration. The separation of studied compounds was performed 
using a 250 X 4.6 mm Supelcosil LC-CN  column with a particle size 
of 5 im (Sigma-Aldrich, Germany) protected with a guard column (20  
X 4  mm) with the same packing material. The mobile phase consisted 
of 50 mM potassium dihydrogen phosphate (pH = 4 .6), methanol, 
and acetonitrile mixed at a ratio of 51 :40 :9  v /v /v  and run at 1 m L/ 
min. Chromatographic analysis was carried out at 25 °C and the 
analytical wavelength was 205 nm.
PAMPA Assay. The ability to passive transport across a cell 
membrane was determined by precoated PAMPA Plate System 
Gentest (Corning, Tewksbury, MA, USA) according to described 
previously protocols.54,55 The compounds’ concentrations in acceptor 
and donor wells were estimated by the U P L C -M S  analyses, which 
were performed by LC /M S Waters ACQUITY TQD system with the 
T Q  Detector (Waters, Milford, USA). The permeability coefficients 
(Pe, cm /s) were calculated according described previously formulas.57
The substrates of Pgp were determined by the luminescent Pgp- 
Glo Assay System (Promega, Madison, WI, USA). The test measures 
luminescently the ATP consuming by Pgp in the presence of 
substrates. The assay was performed in triplicate as described 
previously.55 Tested compounds (100  ^M ) were incubated with 
Pgp membranes for 40  min at 37 °C. The positive (VL) and negative 
(C FN ) controls were incubated at 200 and 100 ^M, respectively. 
Basal activity of Pgp was considered as the difference in the
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luminescent signal between samples treated with 100  ^M  of the 
potent and selective Pgp inhibitor (Na3VO4) and untreated samples. 
The luminescence signal was measured by microplate reader EnSpire 
PerkinElmer (Waltham, MA, USA). Caffeine (C FN ) and norfloxacin 
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Hepatotoxicity. The hepatotoxicity was investigated with use of a 
hepatoma HepG2 (A TCC H B-8065) cell line. Cells were grown 
under described previously conditions.54 The cells viability was 
determined by CellTiter 96  AQueous Non-Radioactive Cell 
Proliferation Assay (Promega, Madison, WI, USA) after 72 h of 
incubation with tested compounds at a final concentration range 
(0 .1—100 ^M ). The reference toxins CCCP and doxorubicin (D X) 
were used at 10 and 1 ^M, respectively. The absorbance was 
measured using a microplate reader EnSpire (PerkinElmer, Waltham, 
MA USA) at 490  nm. The compounds and references were tested in 
quadruplicate. D X was purchased from Sigma-Aldrich (St. Louis, MO, 
USA).
Extended Selectivity Studies. The off-target receptor screen and 
cardiac toxicity (hERG automated patch-clamp method) assays were 
performed by Eurofins Pharma Discovery Services according to well- 
known methods. Further methodological details are available on the 
company web site (www.eurofinsdiscoveryservices.com) and the 
appropriate publications.58 65
In Vivo P harm acod yn am ics Studies. Animals. The experiments 
were performed on male Wistar rats (1 7 0 —200 g) obtained from an 
accredited animal facility at the Jagiellonian University Medical 
College, Krakow, Poland. The animals were housed in groups of four 
in a controlled environment (ambient temperature 21 ±  2 °C ; relative 
humidity 5 0 -6 0 % ; 12 h light/dark cycles (lights on at 8 :00). 
Standard laboratory food (LSM -B) and filtered water were freely 
available. Animals were housed for a period of 6  days in polycarbonate 
Makrolon type 3 cages (dimensions 26.5 X  15 X  42  cm, “open top”) 
without enrichment environment (only wooden shavings litter). Each 
animal was assigned randomly to treatment groups and only used 
once (no repeated use of animals). All the experiments were 
performed by two observers unaware of the treatment applied 
between 9 :0 0  and 14:00 on separate groups of animals. All 
experimental procedures involving animals were conducted in 
accordance with European Union (Directive 2 0 1 0 /6 3 /E U ) and 
Polish legislation acts concerning animal experimentation and 
approved by the II Local Ethics Committee for Experiments on 
Animals in Cracow, Poland (approval number: 108 /2 0 1 6 ). All efforts 
were made to minimize suffering and to reduce the number of animals 
used in the experiments and to use only the number of animals 
necessary to produce reliable scientific data. Each experimental group 
consisted of 6 - 8  animals.
Drugs. All drugs were dissolved in distilled water immediately 
before administration in a volume of 2 mL/kg. The examined 
compounds were administered orally 60 min before tests. In 
antagonism experiments, W AY100635 (Tocris, UK) was administered 
subcutaneously 75 min before testing. Control animals received 
vehicle (distilled water) according to the same schedule.
Porsolt FST. The experiment was carried out according to the 
method of Porsolt et al.66 On the first day of an experiment, the 
animals were individually gently placed in plexiglas cylinders (40  cm  
high, 18 cm in diameter) containing 17 cm of water maintained at 
2 3 - 2 5  °C  for 15 min. On removal from water, the rats were placed 
for 30 min in a plexiglas box under a 60 W  bulb to dry. On the 
following day (2 4  h later), the rats were re-placed in the cylinder after 
administration of test compounds and the total duration of 
immobility was recorded during the 5-min test period. Immobility 
was considered to occur when no additional activity was observed 
other than that necessary to keep the rat’s head above the water.67 
Fresh water was used for each animal.
Lower Lip Retraction. Observations were made according to the 
method described by Kleven et al.68 Animals were observed 
individually during a 10  min period for 10  s of observation per 
animal. During each of these observation periods, the uninterrupted 
presence for at least 3 s (1 ) or absence (0 ) of LLR was recorded. This
cycle was repeated 10  times over a 10  min period; thus, the incidence 
of a particular behavior could vary from 0 to 1 0 .
S tatistical A nalysis. The data of behavioral studies were 
evaluated by an analysis of variance: one-way ANOVA (when one 
drug was given) or two-way ANOVA (when two drugs were used) 
followed by Bonferroni’s post hoc test (statistical significance set at p
< 0.05).
In Vivo P harm acok in etics Studies. Animals. Male Wistar rats 
weighing 2 0 0 -2 5 0  g were used in this study. The investigated 
compounds were dissolved in water and administered orally at three 
different doses, that is, 0.31, 0.63, and 1.25 mg/kg (5 6 )  and 0.04, 
0.16, 0.63 mg/kg (4 4 ). One hour following compound admin­
istration, the animals were sacrificed by decapitation and blood and 
brains were harvested. The blood was allowed to clot at room  
temperature and subsequently centrifuged at 3000 rpm for 10 min 
(Universal 32 centrifuge, Hettich, Germany) to obtain serum. All 
collected samples were frozen at - 8 0  °C  until assayed.
Determination o f  5 6  and 4 4  in Serum  and Brain Tissue. Serum 
and brain concentrations of the studied compounds were measured by 
HPLC with UV detection. The brains were homogenized in distilled 
water (1 :4 , w /v) with a tissue homogenizer T H 220 (Omni 
International, Inc., Warrenton, VA, USA). The extraction of both 
compounds from serum and brain homogenates was performed using 
a mixture of ethyl acetate and hexane (30 :70 , v/v)l. The IS for 56 was
6-[({[1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl]m ethyl}- 
amino)methyl]-N,3-dimethylpyridin-2-amine (0.5 ^g/m L for serum 
samples and 2 ^ g/m L for brain homogenates) and for 4 4  it was (3- 
chloro-4-fluorophenyl)(4-fluoro-4-((((5-methylpyridin-2-yl)methyl)- 
amino)methyl)piperidin-1 -yl)methanone (2  ^g/m L for both serum 
and brain samples) as methanolic solutions.
To isolate 56 and 4 4  from serum (1.5 mL) or brain homogenate (2  
mL) containing these compounds, an appropriate IS (10  ^L) was 
added and the samples were alkalized with 100 ^L of 4  M  NaOH. 
Then, the samples were extracted with 6  mL of the extraction reagent 
by shaking for 20 min (IKA Vibrax VXR, Germany). After 
centrifugation at 3000 rpm for 20 min (Universal 32, Hettich, 
Germany), the organic layers were transferred to new tubes 
containing 150 ^L solution of 0.1 M  H 2SO4 and methanol (90 :10  
v/v). The mixtures were shaken for 20 min and centrifuged for 20  
min (3000  rpm). The organic layer was discarded and 6 0 —80 ^L 
aliquots of the acidic solutions were injected into the HPLC system.
The analytical procedure for ultrafiltrate was similar to that 
described above, with the exception that 300 ^L of this matrix was 
used for analysis, the volumes of 4  M  NaOH and the extraction 
solvent were 20 ^L and 1 mL, respectively, and the organic layers 
were transferred to 100  ^L of the acidic solution.
The HPLC system (LaChrom Elite, Merck-Hitachi, Germany) 
consisted of an L -2130 pump, an L -2200 autosampler, and an L-2420  
UV—VIS detector. EZChrome Elite v. 3.2 (Merck-Hitachi, Germany) 
computer program was used for data acquisition and integration. The 
separation of studied compounds was performed using a 250 X  4.6 
mm Supelcosil LC-CN  column with a particle size of 5 ^m (Sigma- 
Aldrich, Germany) protected with a guard column (2 0  X  4  mm) with 
the same packing material. The mobile phase consisted of 50 mM  
potassium dihydrogen phosphate (pH = 4 .6 ) , methanol, and 
acetonitrile mixed at a ratio of 51:40:9, v /v /v  and run at 1 m L/ 
min. Chromatographic analysis was carried out at 25 °C and the 
analytical wavelength was 205 nm.
The calibration curves were constructed by plotting the ratio of 
peak areas of the studied compound to that of an appropriate IS 
versus the compound concentration. They were linear in the 
concentration range of 0 .5 - 5  ng/m L for 56 and 0 .2 5 -5  ng/m L for 
4 4  in serum and 1—50 ng/g for 56 and 5—100 ng/g for 4 4  in brain 
homogenate. In the case of ultrafiltrate, the calibration curves were 
linear in the range of 5 - 7 0 0  ng/m L for both compounds. The lower 
limit of quantification for all biological matrices studied was the lowest 
calibration standard on the calibration curve, which after extraction 
procedure was analyzed with a coefficient of variation (CV ) of <20%  
and a relative error of <20%. No interfering peaks were observed in 
the chromatograms. The assays were reproducible with low intra- and
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inter-day variation (C V  < 10%). The concentrations were expressed 
in ng/m L of serum or ultrafiltrate and ng/g of wet brain tissue.
Determination o f  in Vitro Rat Plasma Protein Binding. Fresh
blood was harvested from male adult Wistar rats that were sacrificed 
by exsanguination. The blood was allowed to clot for 20 min at room  
temperature and then centrifuged at 3000 rpm for 10 min (Universal 
32, Hettich, Germany). 56 and 4 4  dissolved in water were added in 
volume of 10 ^L to separate glass tubes containing 1 mL aliquots of 
rat serum to achieve final concentrations of 3 and 30 ^ g/m L each. All 
tests were run in triplicate. After vortexing, the serum samples were 
incubated in a water bath at 37 °C for 30 min with gentle shaking. 
Following this incubation period, 100 ^L of serum samples from each 
tube were transferred to Eppendorf tubes and frozen at - 8 0  °C for 
analysis. The remaining serum was transferred into Centrifree 
ultrafiltration devices with Ultracel regenerated cellulose membrane 
(Merck, Darmstadt, Germany) and centrifuged at 1000g for 15 min 
(EBA III centrifuge, Hettich, Germany). The collected ultrafiltrates 
were frozen ( - 8 0  °C ) for further analysis.
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